

# Mammalian O6-alkylguanine-DNA alkyltransferase: regulation and sensitivity to alkylating carcinogenic and therapeutic agents

Cancer Research

50, 6119-29

Citation Report

#	ARTICLE	IF	CITATIONS
1	Localization of the human O6-methylguanine-DNA methyltransferase gene to chromosome 10q24.33-qter. <i>Genomics</i> , 1991, 11, 475-476.	1.3	8
2	Metastases from fresh human non-small cell lung cancers propagated in nude mice. <i>Cancer Letters</i> , 1991, 61, 53-60.	3.2	4
3	Increase of O6-methylguanine-DNA-methyltransferase and N3-methyladenine glycosylase RNA transcripts in rat hepatoma cells treated with DNA-damaging agents. <i>Biochemical and Biophysical Research Communications</i> , 1991, 176, 1086-1092.	1.0	33
4	The signal transduction model of carcinogenesis. <i>Biochemical Pharmacology</i> , 1991, 42, 1511-1523.	2.0	13
5	Inhibition of O6-alkylguanine-DNA alkyltransferase and DNase I activities in vitro by some alkylating substances and antineoplastic agents. <i>Journal of Cancer Research and Clinical Oncology</i> , 1991, 117, 549-555.	1.2	8
6	Widespread adaptive response against environmental methylating agents in microorganisms. <i>Mutation Research - Fundamental and Molecular Mechanisms of Mutagenesis</i> , 1991, 250, 211-221.	0.4	39
7	Effect of O6-alkylguanine-DNA alkyltransferase on the frequency and spectrum of mutations induced by N-methyl-N-nitrosoguanidine in the HPRT gene of diploid human fibroblasts. <i>Mutation Research - Fundamental and Molecular Mechanisms of Mutagenesis</i> , 1991, 250, 397-409.	0.4	65
8	Expression of human O6-methylguanine-DNA methyltransferase in chinese hamster ovary cells and restoration of cellular resistance to certain N-nitroso compounds. <i>Molecular Carcinogenesis</i> , 1991, 4, 482-488.	1.3	16
9	Metastatic behaviour of canine lung carcinoma in autochthonous and xenotransplant hosts. <i>Clinical and Experimental Metastasis</i> , 1991, 9, 567-577.	1.7	4
10	Notes on the use of in vitro systems to investigate the activity and the mechanism of action of antineoplastic agents. <i>Cytotechnology</i> , 1991, 5, 15-18.	0.7	0
11	Inducibility of the DNA repair gene encoding O6-methylguanine-DNA methyltransferase in mammalian cells by DNA-damaging treatments. <i>Molecular and Cellular Biology</i> , 1991, 11, 4660-4668.	1.1	122
12	O6-methylguanine inhibits the binding of transcription factors to DNA. <i>Nucleic Acids Research</i> , 1991, 19, 5739-5742.	6.5	25
13	Inactive O6-methylguanine-DNA methyltransferase in human cells. <i>Nucleic Acids Research</i> , 1992, 20, 6081-6090.	6.5	13
14	Inducible alkyltransferase DNA repair proteins in the filamentous fungus <i>Aspergillus nidulans</i> . <i>Nucleic Acids Research</i> , 1992, 20, 645-651.	6.5	25
15	Self-destruction and tolerance in resistance of mammalian cells to alkylation damage. <i>Nucleic Acids Research</i> , 1992, 20, 2933-2940.	6.5	163
16	The <i>Saccharomyces cerevisiae</i> MGT1 DNA repair methyltransferase gene: its promoter and entire coding sequence, regulation and in vivo biological functions. <i>Nucleic Acids Research</i> , 1992, 20, 3599-3606.	6.5	44
17	Fidelity of replication of the leading and the lagging DNA strands opposite N-methyl-N-nitrosourea-induced DNA damage in human cells. <i>Nucleic Acids Research</i> , 1992, 20, 6543-6548.	6.5	14
18	O6-alkylguanine-DNA-alkyltransferase activity and nitrosourea sensitivity in human cancer cell lines. <i>British Journal of Cancer</i> , 1992, 66, 840-843.	2.9	36

#	ARTICLE	IF	CITATIONS
19	Relationship between O6-alkylguanine-DNA alkyltransferase activity and N-methyl-N'-nitro-N-nitrosoguanidine-induced mutation, transformation, and cytotoxicity in C3H/10T1/2 cells expressing exogenous alkyltransferase genes.. Proceedings of the National Academy of Sciences of the United States of America, 1992, 89, 11199-11203.	3.3	21
20	Cyclophosphamide decreases O6-alkylguanine-DNA alkyltransferase activity in peripheral lymphocytes of patients undergoing bone marrow transplantation. British Journal of Cancer, 1992, 66, 331-336.	2.9	13
21	Cholecystokinin inhibits DNA alkylation induced by N-nitrosobis (2-oxopropyl)amine (BOP) in hamster pancreas. Cancer Letters, 1992, 62, 251-256.	3.2	9
22	Genomic differences between O6-methylguanine-DNA methyltransferase proficient (Mex+) and deficient (Mex <sup>-</sup> ) cell lines: Possible role of genetic and epigenetic changes in conversion of Mex+ into Mex <sup>-</sup> . Biochemical and Biophysical Research Communications, 1992, 183, 1184-1190.	1.0	16
23	DT-diaphorase activity correlates with sensitivity to the indoloquinone EO9 in mouse and human colon carcinomas. European Journal of Cancer, 1992, 28, 1597-1600.	1.3	58
24	O6-Alkylguanine-DNA alkyltransferase activity in human malignant melanoma. Journal of Dermatological Science, 1992, 4, 6-10.	1.0	16
25	Effect of neonatal exposure to 5-bromo-2 <sup>deoxy</sup> uridine on life span, estrus function and tumor development in rats – an argument in favor of the mutation theory of aging?. Mutation Research - DNAging, 1992, 275, 97-110.	3.3	17
26	Formation and disappearance of DNA interstrand cross-links in human colon tumor cell lines with different levels of resistance to chlorozotocin. Biochemical Pharmacology, 1992, 43, 1159-1163.	2.0	7
27	In vivo depletion of O6-alkylguanine-DNA-alkyltransferase in lymphocytes and melanoma of patients treated with CB 10-277, a new DTIC analogue. Cancer Chemotherapy and Pharmacology, 1992, 31, 240-246.	1.1	9
28	O 6-Alkylguanine-DNA alkyltransferase content in synchronised human cancer cells. Cancer Chemotherapy and Pharmacology, 1992, 30, 77-80.	1.1	6
29	Immunohistological examination of the inter- and intracellular distribution of O6-alkylguanine DNA-alkyltransferase in human liver and melanoma. British Journal of Cancer, 1992, 66, 355-360.	2.9	50
30	Mechanisms of action of, and modes of resistance to, alkylating agents used in the treatment of haematological malignancies. Blood Reviews, 1992, 6, 163-173.	2.8	185
31	O6-methylguanine-dna methyltransferase activity and sensitivity of 20 chinese tumor cell strains to l-(4-amino-2-methyl-5-pyrimidinyl) methyl-3- (2-chloroethyl)-3-nitrosourea. Chinese Journal of Cancer Research: Official Journal of China Anti-Cancer Association, Beijing Institute for Cancer Research, 1992, 4, 11-16.	0.7	0
32	Chinese hamster ovary cells deficient or proficient in O6-alkylguanine-DNA alkyltransferase activity are equally sensitive to X-rays. Mutation Research-Fundamental and Molecular Mechanisms of Mutagenesis, 1992, 283, 125-129.	1.2	4
33	Stress factors affecting expression of O6-methylguanine-DNA methyltransferase mRNA in rat hepatoma cells. Biochimica Et Biophysica Acta Gene Regulatory Mechanisms, 1992, 1171, 35-40.	2.4	31
34	Isolation and partial characterization of murine O6-alkylguanine-DNA-alkyltransferase: Comparative sequence and structural properties. Molecular Carcinogenesis, 1992, 5, 161-169.	1.3	18
35	Tissue-specific expression and induction of human O6-alkylguanine-dna alkyltransferase in transgenic mice. Molecular Carcinogenesis, 1992, 6, 26-31.	1.3	8
36	Mutagenesis and transgenic systems: Perspective from the mutagen, N-ethyl-N-nitrosourea. Environmental and Molecular Mutagenesis, 1993, 22, 1-6.	0.9	27

#	ARTICLE	IF	CITATIONS
37	Contribution of O6-alkylguanine and N-alkylpurines to the formation of sister chromatid exchanges, chromosomal aberrations, and gene mutations: New insights gained from studies of genetically engineered mammalian cell lines. <i>Environmental and Molecular Mutagenesis</i> , 1993, 22, 283-292.	0.9	115
38	Role of DNA repair in the mechanisms of cell resistance to alkylating agents and cisplatin. <i>Cancer Chemotherapy and Pharmacology</i> , 1993, 32, 85-89.	1.1	49
39	Effect of O6-benzylguanine on the response to 1,3-bis(2-chloroethyl)-1-nitrosourea in the Dunning R3327G model of prostatic cancer. <i>Cancer Chemotherapy and Pharmacology</i> , 1993, 32, 221-225.	1.1	27
40	Effect of temozolomide and dacarbazine on O6-alkylguanine-DNA alkyltransferase activity and sensitivity of human tumor cells and xenografts to 1,3-bis(2-chloroethyl)-1-nitrosourea. <i>Cancer Chemotherapy and Pharmacology</i> , 1993, 32, 59-63.	1.1	43
41	Treatment of subcutaneous and intracranial brain tumor xenografts with O6-benzylguanine and 1,3-bis(2-chloroethyl)-1-nitrosourea. <i>Cancer Chemotherapy and Pharmacology</i> , 1993, 32, 471-476.	1.1	61
42	The effects of O6-benzylguanine and hypoxia on the cytotoxicity of 1,3-bis(2-chloroethyl)-1-nitrosourea in nitrosourea-resistant SF-763 cells. <i>Cancer Chemotherapy and Pharmacology</i> , 1993, 32, 477-481.	1.1	19
43	Molecular analysis of ethylene oxide-induced mutations at the HPRT locus in human diploid fibroblasts. <i>Mutation Research - Fundamental and Molecular Mechanisms of Mutagenesis</i> , 1993, 287, 283-292.	0.4	37
44	ENU-induced mutagenesis at a single A:T base pair in transgenic mice containing $\hat{I}_1$ X174. <i>Mutation Research - Environmental Mutagenesis and Related Subjects Including Methodology</i> , 1993, 292, 69-81.	0.4	48
45	Synergistic efficacy of O6-benzylguanine and 1,3-bis(2-chloroethyl)-1-nitrosourea (BCNU) in a human colon cancer xenograft completely resistant to BCNU alone. <i>Biochemical Pharmacology</i> , 1993, 45, 483-491.	2.0	68
46	Effect of O6-benzylguanine on the sensitivity of human colon tumor xenografts to 1,3-BIS(2-chloroethyl)-1-nitrosourea (BCNU). <i>Biochemical Pharmacology</i> , 1993, 46, 285-290.	2.0	58
47	Effect of N-(n-butyl)-1,3-diaminopropane on polyamine metabolism, cell growth and sensitivity to chloroethylating agents. <i>Biochemical Pharmacology</i> , 1993, 46, 717-724.	2.0	13
48	Regulation of Repair of Alkylation Damage in Mammalian Genomes. <i>Progress in Molecular Biology and Translational Science</i> , 1993, 44, 109-142.	1.9	143
49	Antitumor alkylating agents: in vitro cross-resistance and collateral sensitivity studies. <i>Cancer Chemotherapy and Pharmacology</i> , 1993, 33, 113-122.	1.1	33
50	Expression of O6-alkylguanine-DNA-alkyltransferase in situ in ovarian and Hodgkin's tumours. <i>European Journal of Cancer</i> , 1993, 29, 1306-1312.	1.3	21
51	Formation of promutagenic methylation damage in tissue-DNA of mice treated with antischistosomal agents. <i>Cancer Letters</i> , 1993, 75, 167-173.	3.2	9
52	Anticancer drug screening and discovery in the 1990s: a European perspective. <i>European Journal of Cancer</i> , 1993, 29, 3-14.	1.3	33
53	Deficient repair of DNA lesion O6-methylguanine in cirrhosis. <i>Lancet, The</i> , 1993, 341, 207-208.	6.3	17
54	Involvement of 10q22 in leiomyoma. <i>Cancer Genetics and Cytogenetics</i> , 1993, 69, 132-135.	1.0	34

#	ARTICLE	IF	CITATIONS
55	Sequential administration of varying doses of dacarbazine and fotemustine in advanced malignant melanoma. <i>British Journal of Cancer</i> , 1993, 67, 1356-1360.	2.9	40
56	O6-Methylguanine-DNA Methyltransferase in Human Normal and Malignant Lung Tissues. <i>Cancer Investigation</i> , 1993, 11, 258-263.	0.6	16
57	The prevention of thymic lymphomas in transgenic mice by human O6-alkylguanine-DNA alkyltransferase. <i>Science</i> , 1993, 259, 219-222.	6.0	245
58	Protection against chloroethylnitrosourea cytotoxicity by eukaryotic 3-methyladenine DNA glycosylase.. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 1993, 90, 11855-11859.	3.3	38
59	The relevance of pharmacology in clinical oncology practice. <i>Annals of Oncology</i> , 1993, 4, 466-469.	0.6	4
60	Specificities of human, rat and <i>E. coli</i> O6-methylguanine-DNA methyltransferases towards the repair of O6-methyl and O6-ethylguanine in DNA. <i>Nucleic Acids Research</i> , 1994, 22, 1613-1619.	6.5	33
61	Immunocytochemical evidence for a nuclear and a cytoplasmic O <sup>6</sup> -methylguanine repair mechanism in cultured rat hepatocytes. <i>Journal of Toxicology and Environmental Health - Part A: Current Issues</i> , 1994, 43, 441-451.	1.1	2
62	Potential of O6-methylguanine or O6-benzylguanine in the enhancement of chloroethylnitrosourea cytotoxicity on brain tumours. <i>Acta Neurochirurgica</i> , 1994, 128, 13-20.	0.9	6
63	Chromosome aberrations induced in vitro: Mechanisms, delayed expression, and intriguing questions. <i>Environmental and Molecular Mutagenesis</i> , 1994, 23, 44-53.	0.9	49
64	Enhancing effect of O6-alkylguanine derivatives on chloroethylnitrosourea cytotoxicity toward tumor cells. <i>International Journal of Cancer</i> , 1994, 58, 706-712.	2.3	18
65	DNA damage tolerance, mismatch repair and genome instability. <i>BioEssays</i> , 1994, 16, 833-839.	1.2	279
66	Genotoxic and cytotoxic effects of 4-aryl-1-nitrosourea-carboxamides on O <sup>6</sup> -alkylguanine-DNA alkyltransferase-positive and-negative human cell lines. <i>Journal of Cancer Research and Clinical Oncology</i> , 1994, 120, 403-408.	1.2	2
67	Alkyltransferase transgenic mice: probes of chemical carcinogenesis. <i>Mutation Research - Fundamental and Molecular Mechanisms of Mutagenesis</i> , 1994, 307, 541-555.	0.4	19
68	Molecular electric field mapping and structure-activity relationships for some human O6-alkylguanine-DNA alkyl transferase depleting agents. <i>Computational and Theoretical Chemistry</i> , 1994, 315, 203-207.	1.5	7
69	In vitro methylation of the human O6-methylguanine-DNA methyltransferase promoter reduces transcription. <i>Biochimica Et Biophysica Acta Gene Regulatory Mechanisms</i> , 1994, 1217, 141-146.	2.4	29
70	Repair of O6-alkylguanines in the nuclear DNA of human lymphocytes and leukaemic cells: analysis at the single-cell level. <i>British Journal of Cancer</i> , 1994, 69, 698-705.	2.9	25
71	Effects of Inhibition of O6-Alkylguanine-DNA Alkyltransferase in Rats on Carcinogenesis by Methylnitrosourea and Ethylnitrosourea. <i>Japanese Journal of Cancer Research</i> , 1994, 85, 226-230.	1.7	11
72	Biodistribution of O <sup>6</sup> -benzylguanine and its effectiveness against human brain tumor xenografts when given in polyethylene glycol or cremophor-EL. <i>Cancer Chemotherapy and Pharmacology</i> , 1994, 35, 121-126.	1.1	15

#	ARTICLE	IF	CITATIONS
73	Sequential therapy with dacarbazine and carmustine: a phase I study. <i>Cancer Chemotherapy and Pharmacology</i> , 1994, 34, 509-514.	1.1	9
74	Combined depletion of O6-alkylguanine-DNA alkyltransferase and glutathione to modulate nitrosourea resistance in breast cancer. <i>Biochemical Pharmacology</i> , 1994, 48, 543-548.	2.0	16
75	Intracellular localization and function of DNA repair methyltransferase in human cells. <i>Mutation Research DNA Repair</i> , 1994, 315, 199-212.	3.8	29
76	O6-Alkylguanine-DNA alkyltransferase activity in schistosomiasis-associated human bladder cancer. <i>European Journal of Cancer</i> , 1994, 30, 1314-1319.	1.3	26
77	Formation and loss of O6-methyldeoxyguanosine in human leucocyte DNA following sequential DTIC and fotemustine chemotherapy. <i>British Journal of Cancer</i> , 1994, 69, 853-857.	2.9	22
78	The Escherichia coli AlkB protein protects human cells against alkylation-induced toxicity. <i>Journal of Bacteriology</i> , 1994, 176, 6255-6261.	1.0	65
79	Potential of the Cytotoxicity of Chloroethylnitrosourea by O6-Arylmethylguanines.. <i>Biological and Pharmaceutical Bulletin</i> , 1995, 18, 424-430.	0.6	19
80	Contribution of O6-methylguanine-DNA methyltransferase to monofunctional alkylating-agent resistance in human brain tumor-derived cell lines. <i>Molecular Carcinogenesis</i> , 1995, 13, 70-80.	1.3	35
81	Contribution of O6-methylguanine-DNA methyltransferase to resistance to 1,3-(2-chloroethyl)-1-nitrosourea in human brain tumor-derived cell lines. <i>Molecular Carcinogenesis</i> , 1995, 13, 81-88.	1.3	43
82	O6-methylguanine-DNA methyltransferase activity in breast and brain tumors. <i>International Journal of Cancer</i> , 1995, 61, 321-326.	2.3	83
83	Differential inactivation of O6-methylguanine-dna methyltransferase activity by O6-arylmethylguanines. <i>International Journal of Cancer</i> , 1995, 63, 148-151.	2.3	19
84	Perspectives on molecular assays for measuring mutation in humans and rodents. <i>Environmental and Molecular Mutagenesis</i> , 1995, 25, 88-101.	0.9	11
85	Positive correlation between cellular glutathione and acquired cisplatin resistance in human ovarian cancer cells. <i>Cell Biology and Toxicology</i> , 1995, 11, 273-281.	2.4	24
86	O6-methylguanine-DNA methyltransferase activities in biopsies of human melanoma tumours. <i>British Journal of Cancer</i> , 1995, 71, 37-39.	2.9	19
87	Sensitization of human colon tumour cell lines to carmustine by depletion of O6-alkylguanine-DNA alkyltransferase. <i>Journal of Cancer Research and Clinical Oncology</i> , 1995, 121, 225-229.	1.2	15
88	Mutations induced by dacarbazine activated with cytochrome P-450. <i>Mutation Research - Fundamental and Molecular Mechanisms of Mutagenesis</i> , 1995, 327, 113-120.	0.4	10
89	Genotoxicity of 1,3-bis(2-chloroethyl)-1-nitrosourea (BCNU). <i>Mutation Research - Reviews in Genetic Toxicology</i> , 1995, 339, 91-119.	3.0	45
90	Streptozotocin-induced genotoxic effects in Chinese hamster cells: The resistant phenotype of V79 cells. <i>Mutation Research-Fundamental and Molecular Mechanisms of Mutagenesis</i> , 1995, 347, 79-85.	1.2	10

#	ARTICLE	IF	CITATIONS
91	Chemosensitivity to triazene compounds and O6-alkylguanine-DNA alkyltransferase levels: Studies with blasts of leukaemic patients. <i>Annals of Oncology</i> , 1995, 6, 389-393.	0.6	41
92	O 6 -Alkylguanine-DNA Alkyltransferase: A Target for the Modulation of Drug Resistance. <i>Hematology/Oncology Clinics of North America</i> , 1995, 9, 431-450.	0.9	48
93	Applications of molecular biology to biomedicine and toxicology. <i>Journal of Environmental Science and Health, Part C: Environmental Carcinogenesis and Ecotoxicology Reviews</i> , 1995, 13, 1-51.	2.9	10
94	Patterns of Drug Resistance Parameters in Adult Leukemia. <i>Leukemia and Lymphoma</i> , 1995, 17, 101-109.	0.6	16
95	Inactivation of O6-methylguanine-DNA methyltransferase in vivo by SN2 alkylating agents. <i>Mutation Research DNA Repair</i> , 1995, 336, 61-67.	3.8	8
96	Enhanced host cell reactivation capacity and expression of DNA repair genes in human breast cancer cells resistant to bi-functional alkylating agents. <i>Mutation Research DNA Repair</i> , 1995, 337, 179-189.	3.8	31
97	Constitutive expression and inducibility of O6-methylguanine-DNA methyltransferase and N-methylpurine-DNA glycosylase in rat liver cells exhibiting different status of differentiation. <i>Biochimica Et Biophysica Acta - Molecular Basis of Disease</i> , 1995, 1270, 63-72.	1.8	33
98	High-dose chemotherapy regimens for solid tumors. <i>Cancer Treatment Reviews</i> , 1995, 21, 105-132.	3.4	72
99	Increased killing of prostate, breast, colon, and lung tumor cells by the combination of inactivators of O6-alkylguanine-DNA alkyltransferase and N,Nâ€™-bis(2-chloroethyl)-N-nitrosourea. <i>Biochemical Pharmacology</i> , 1995, 50, 1141-1148.	2.0	39
100	Structure, Function, and Inhibition of O6-Alkylguanine-DNA Alkyltransferase. <i>Progress in Molecular Biology and Translational Science</i> , 1995, 51, 167-223.	1.9	417
101	Inhibition of O6-alkylguanine-DNA alkyltransferase in animal and human ovarian tumor cell lines by O6-benzylguanine and sensitization to BCNU. <i>Cancer Chemotherapy and Pharmacology</i> , 1995, 35, 262-266.	1.1	7
102	Investigation of chemoresistance-related genes mRNA expression for selecting anticancer agents in successful adjuvant chemotherapy for a case of recurrent glioblastoma. <i>World Neurosurgery</i> , 1995, 44, 462-470.	1.3	22
103	EPIDEMIOLOGY OF PRIMARY CNS NEOPLASMS. <i>Neurologic Clinics</i> , 1996, 14, 273-290.	0.8	94
104	Quantification of O 6 -methylguanine-DNA methyltransferase mRNA in human brain tumors. <i>Biochimica Et Biophysica Acta - General Subjects</i> , 1996, 1289, 105-109.	1.1	19
105	Thymidine kinase deficient cells with decreased TTP pools are hypersensitive to DNA alkylating agents. <i>Mutation Research DNA Repair</i> , 1996, 362, 119-125.	3.8	10
106	Amino acid residues affecting the activity and stability of human O6-alkylguanine-DNA alkyltransferase. <i>Mutation Research DNA Repair</i> , 1996, 363, 15-25.	3.8	47
107	Enhancement effect of O6-Fluorobenzylguanines on chloroethylnitrosourea cytotoxicity in tumor cells. <i>Life Sciences</i> , 1996, 58, PL303-PL308.	2.0	3
108	Retrovirus-mediated transfer of the human O6-Methylguanine-DNA methyltransferase gene into a murine hematopoietic stem cell line and resistance to the toxic effects of certain alkylating agents. <i>Biochemical Pharmacology</i> , 1996, 51, 1221-1228.	2.0	25

#	ARTICLE	IF	CITATIONS
109	The role of DNA repair in the prevention of cancer. <i>Molecular Aspects of Medicine</i> , 1996, 17, 235-383.	2.7	6
110	Localization of O6-alkylguanine transferase in cancer susceptible cells of human female breast. <i>Cancer Letters</i> , 1996, 108, 111-118.	3.2	1
111	Analysis of O6-methylguanine-DNA methyltransferase mRNA in fine needle biopsies from human melanoma metastases by reverse transcription and polymerase chain reaction. <i>European Journal of Cancer</i> , 1996, 32, 2319-2326.	1.3	7
112	Molecular electrostatic potentials and fields: hydrogen bonding, recognition, reactivity and modelling. <i>Theoretical and Computational Chemistry</i> , 1996, , 257-296.	0.2	28
113	Conformation and dynamics of the mispair O 6-ethylguanine: thymine. <i>Journal of the Chemical Society, Faraday Transactions</i> , 1996, 92, 1353.	1.7	1
114	Retroviral transduction of a mutant methylguanine DNA methyltransferase gene into human CD34 cells confers resistance to O6-benzylguanine plus 1,3-bis(2-chloroethyl)-1-nitrosourea. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 1996, 93, 14088-14093.	3.3	78
115	3-methyladenine-DNA-glycosylase and O6-alkyl guanine-DNA-alkyltransferase activities and sensitivity to alkylating agents in human cancer cell lines. <i>British Journal of Cancer</i> , 1996, 73, 861-865.	2.9	17
116	Chemotherapy Resistance Mechanisms. <i>Acta OncolÃ³gica</i> , 1996, 35, 76-80.	0.8	18
117	Methylation of CpG Island Transcription Factor Binding Sites Is Unnecessary for Aberrant Silencing of the Human MGMT Gene. <i>Journal of Biological Chemistry</i> , 1996, 271, 13916-13924.	1.6	72
118	Potential of testicular cytotoxicity by the alkyltransferase inhibitor O6 benzylguanine and the 5-fluorouracil/N-(2-chloroethyl)-N-nitrosourea molecular combination, B.4152. <i>Reproductive Toxicology</i> , 1996, 10, 71-77.	1.3	4
119	Mutational spectra induced under distinct excision repair conditions by the 3 methylating agents N-methyl-N-nitrosourea, N-methyl-N-â€²-nitro-N-nitrosoguanidine and N-nitrosodimethylamine in postmeiotic male germ cells of <i>Drosophila</i> . <i>Mutation Research - Fundamental and Molecular Mechanisms of Mutagenesis</i> , 1996, 352, 97-115.	0.4	21
120	DNA damage, and repair in mutagenesis and carcinogenesis: implications of structure-activity relationships for cross-species extrapolation. <i>Mutation Research - Fundamental and Molecular Mechanisms of Mutagenesis</i> , 1996, 353, 177-218.	0.4	51
121	Formation and Persistence of N<sup>7</sup>- and O<sup>6</sup>-Methylâ€¢Guanine in DNA of Chick Embryo Brain Cells <i>in ovo</i> Following Administration of N-â€¢Nitrosoâ€¢N-â€¢Methylurea. <i>Transboundary and Emerging Diseases</i> , 1996, 43, 589-598.	0.6	4
122	DNA adducts: biological markers of exposure and potential applications to risk assessment. <i>Mutation Research - Reviews in Genetic Toxicology</i> , 1996, 365, 129-146.	3.0	112
123	Effect of Alcohol Drinking on Gene Expression of Hepatic O6-Methylguanine DNA Methyltransferase in Chronic Liver Diseases. <i>Alcoholism: Clinical and Experimental Research</i> , 1996, 20, 297A-300A.	1.4	11
124	Significance of cell type specific formation and elimination of DNA-adducts in respiratory tissues of hamster and rat induced by alkylating chemical carcinogens. <i>Experimental and Toxicologic Pathology</i> , 1996, 48, 544-547.	2.1	1
125	Protective effect of O6-methylguanine-DNA methyltransferase (MGMT) on the cytotoxic and recombinogenic activity of different antineoplastic drugs. , 1996, 65, 506-512.		66
126	Chemoprotection of normal tissues by transfer of drug resistance genes. <i>Cancer and Metastasis Reviews</i> , 1996, 15, 365-383.	2.7	42



#	ARTICLE	IF	CITATIONS
127	O6-benzylguanine enhances the sensitivity of a glioma xenograft with low O6-alkylguanine-DNA alkyltransferase activity to temozolomide and BCNU. <i>British Journal of Cancer</i> , 1996, 73, 1049-1052.	2.9	71
128	3-aminobenzamide and/or O6-benzylguanine evaluated as an adjuvant to temozolomide or BCNU treatment in cell lines of variable mismatch repair status and O6-alkylguanine-DNA alkyltransferase activity. <i>British Journal of Cancer</i> , 1996, 74, 1030-1036.	2.9	108
129	Replication across O6-Methylguanine by Human DNA Polymerase $\beta$ in Vitro. <i>Journal of Biological Chemistry</i> , 1996, 271, 28391-28398.	1.6	35
130	Detection of DNA methylation adducts in Hodgkin's disease patients treated with procarbazine. <i>Biomarkers</i> , 1996, 1, 226-231.	0.9	4
131	Mismatch Repair Defects and O6-Methylguanine-DNA Methyltransferase Expression in Acquired Resistance to Methylating Agents in Human Cells. <i>Journal of Biological Chemistry</i> , 1997, 272, 28596-28606.	1.6	53
132	Amplification of the DNA Repair Gene O6-Methylguanine-DNA Methyltransferase Associated with Resistance to Alkylating Drugs in a Mammalian Cell Line. <i>Journal of Biological Chemistry</i> , 1997, 272, 13250-13254.	1.6	12
133	Methylation of Discrete Regions of the O6-Methylguanine DNA Methyltransferase (MGMT) CpG Island Is Associated with Heterochromatinization of the MGMT Transcription Start Site and Silencing of the Gene. <i>Molecular and Cellular Biology</i> , 1997, 17, 5612-5619.	1.1	206
134	Nitrosamine Carcinogenesis: Rodent Assays, Quantitative Structure-Activity Relationships, and Human Risk Assessment. <i>Drug Metabolism Reviews</i> , 1997, 29, 1055-1078.	1.5	21
135	Synthesis of 2-substituted 2'-deoxyguanosines and 6-O-allylguanines via the activation of C-2 by a trifluoromethanesulfonate group. <i>Journal of the Chemical Society Perkin Transactions 1</i> , 1997, , 1887-1894.	0.9	8
136	Role of O6-methylguanine-DNA methyltransferase, glutathione transferase M3-3 and glutathione in resistance to carmustine in a human non-small cell lung cancer cell line. <i>European Journal of Cancer</i> , 1997, 33, 447-452.	1.3	9
137	Immunohistochemical examination of the expression of O6-methylguanine-DNA methyltransferase in human melanoma metastases. <i>European Journal of Cancer</i> , 1997, 33, 129-134.	1.3	19
138	p53 gene mutation in N-butyl-N-(4-hydroxybutyl)nitrosamine-induced urinary bladder tumors and N-methyl-N-nitrosourea-induced colon tumors of rats. <i>Cancer Letters</i> , 1997, 117, 81-86.	3.2	2
139	The relationship of a novel drug-resistant phenotype in C3H10T1/2 cells selected with alkylating agents to neoplastic transformation and ATP metabolism. <i>Cancer Letters</i> , 1997, 113, 195-203.	3.2	1
140	Temozolomide: a review of its discovery, chemical properties, pre-clinical development and clinical trials. <i>Cancer Treatment Reviews</i> , 1997, 23, 35-61.	3.4	717
141	Application of Antisense Ribonucleic Acid Complementary to O6-Methylguanine-deoxyribonucleic Acid Methyltransferase Messenger Ribonucleic Acid for Therapy of Malignant Gliomas. <i>Neurosurgery</i> , 1997, 41, 434-441.	0.6	24
142	Transcription and DNA damage: a link to a kink.. <i>Environmental Health Perspectives</i> , 1997, 105, 145-153.	2.8	23
143	Understanding and manipulating O6-methylguanine-DNA methyltransferase expression. , 1997, 74, 285-297.		62
144	The potential role of glycine-160 of human O6-alkylguanine-DNA alkyltransferase in reaction with O6-benzylguanine as determined by site-directed mutagenesis and molecular modelling comparisons. <i>BBA - Proteins and Proteomics</i> , 1997, 1342, 90-102.	2.1	6

#	ARTICLE	IF	CITATIONS
145	Clonal evolution of N-methylnitrosourea-induced C57BL/6J thymic lymphomas by analysis of multiple genetic alterations. <i>Leukemia Research</i> , 1997, 21, 189-198.	0.4	12
146	Inhibition of DNA repair as a means of increasing the antitumor activity of DNA reactive agents. <i>Advanced Drug Delivery Reviews</i> , 1997, 26, 105-118.	6.6	48
147	Systemic therapy of malignant melanoma. <i>Medical Oncology</i> , 1997, 14, 73-81.	1.2	12
148	A mathematical model for intracellular effects of toxins on DNA adduction and repair. <i>Bulletin of Mathematical Biology</i> , 1997, 59, 89-106.	0.9	5
149	A mathematical model for intracellular effects of toxins on DNA adduction and repair. <i>Bulletin of Mathematical Biology</i> , 1997, 59, 89-106.	0.9	2
150	Nucleotide excision repair and anti-cancer chemotherapy. , 1998, 27, 187-201.		25
151	Drug resistance and DNA repair in leukaemia. <i>Cytotechnology</i> , 1998, 27, 175-185.	0.7	3
152	Initial Levels of Azoxymethane-Induced DNA Methyl Adducts Are Not Predictive of Tumor Susceptibility in Inbred Mice. <i>Toxicology and Applied Pharmacology</i> , 1998, 150, 196-203.	1.3	38
153	Lithocholic Acid, a Putative Tumor Promoter, Inhibits Mammalian DNA Polymerase $\beta$ . <i>Japanese Journal of Cancer Research</i> , 1998, 89, 1154-1159.	1.7	96
154	Efficient protection of cells from the genotoxicity of nitrosoureas by the retrovirus-mediated transfer of human O6-methylguanine-DNA methyltransferase using bicistronic vectors with human multidrug resistance gene 1. <i>Mutation Research - Fundamental and Molecular Mechanisms of Mutagenesis</i> , 1998, 401, 133-141.	0.4	20
155	Comparative mutational spectra of the nitrogen mustard chlorambucil and its half-mustard analogue in Chinese hamster AS52 cells. <i>Mutation Research - Fundamental and Molecular Mechanisms of Mutagenesis</i> , 1998, 401, 153-164.	0.4	17
156	A new model for how O6-methylguanine-DNA methyltransferase binds DNA. <i>Proteins: Structure, Function and Bioinformatics</i> , 1998, 32, 3-6.	1.5	25
157	Platinum-DNA adduct, nucleotide excision repair and platinum based anti-cancer chemotherapy. <i>Cancer Treatment Reviews</i> , 1998, 24, 331-344.	3.4	380
158	Expression of genes involved in nucleotide excision repair and sensitivity to cisplatin and melphalan in human cancer cell lines. <i>European Journal of Cancer</i> , 1998, 34, 1783-1788.	1.3	56
159	The antitumour activity of alkylating agents is not correlated with the levels of glutathione, glutathione transferase and O6-alkylguanine-DNA-alkyltransferase of human tumour xenografts. <i>European Journal of Cancer</i> , 1998, 34, 1749-1755.	1.3	23
160	Arsenic toxicity is enzyme specific and its affects on ligation are not caused by the direct inhibition of DNA repair enzymes. <i>Mutation Research DNA Repair</i> , 1998, 408, 203-218.	3.8	160
161	The sensitization of cells treated with O6-methylguanine to alkylation damage is affected by the number of O6-methylguanine-DNA methyltransferase molecules escaped from inactivation. <i>Mutation Research DNA Repair</i> , 1998, 409, 173-179.	3.8	4
162	Kinetics of the Action of Thymine DNA Glycosylase. <i>Journal of Biological Chemistry</i> , 1998, 273, 20007-20014.	1.6	138

#	ARTICLE	IF	CITATIONS
163	O6-Methylguanine and O6-methylguanine-dna methyltransferase activity in tissues of BDF-1 mice treated with antiparasitic drugs. <i>Toxicology Letters</i> , 1998, 94, 199-208.	0.4	10
164	O6-Alkylguanine-DNA alkyltransferase: influence on susceptibility to the genetic effects of alkylating agents. <i>Toxicology Letters</i> , 1998, 102-103, 53-57.	0.4	7
165	Use of DNA Repair-Deficient XPA Transgenic Mice in Short-Term Carcinogenicity Testing. <i>Toxicologic Pathology</i> , 1998, 26, 742-749.	0.9	36
166	Analysis for regulatory elements in yeastMGMTgene transcription. <i>Korean Journal of Biological Sciences</i> , 1998, 2, 287-295.	0.1	0
167	Implantable Slow-Release Chemotherapeutic Polymers for the Treatment of Malignant Brain Tumors. <i>Cancer Control</i> , 1998, 5, 130-137.	0.7	62
168	Thermostable archaeal O6-alkylguanine-DNA alkyltransferases. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 1998, 95, 6711-6715.	3.3	23
169	Clinical response of O6-methylguanine-DNA methyltransferase levels to 1,3-(2-chloroethyl)-1-nitrosourea chemotherapy in glioma patients. <i>Neurosurgical Focus</i> , 1998, 4, E5.	1.0	1
170	Implication of Localization of Human DNA Repair Enzyme <i>O<sup>6</sup>-Methylguanine-DNA Methyltransferase at Active Transcription Sites in Transcription-Repair Coupling of the Mutagenic O<sup>6</sup>-Methylguanine Lesion</i> . <i>Molecular and Cellular Biology</i> , 1998, 18, 1660-1669.	1.1	33
171	Probing of conformational changes in human O6-alkylguanine-DNA alkyl transferase protein in its alkylated and DNA-bound states by limited proteolysis. <i>Biochemical Journal</i> , 1998, 329, 545-550.	1.7	34
172	Separation of killing and tumorigenic effects of an alkylating agent in mice defective in two of the DNA repair genes. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 1998, 95, 5116-5120.	3.3	124
173	Involvement of the Mismatch Repair System in Temozolomide-Induced Apoptosis. <i>Molecular Pharmacology</i> , 1998, 54, 334-341.	1.0	233
174	Expression Pattern of Chemoresistance-related Genes in Human Malignant Brain Tumors: A Working Knowledge for Proper Selection of Anticancer Drugs. <i>Japanese Journal of Clinical Oncology</i> , 1999, 29, 527-534.	0.6	12
175	Combined mismatch and nucleotide excision repair defects in a human cell line: mismatch repair processes methylation but not UV- or ionizing radiation-induced DNA damage. <i>Carcinogenesis</i> , 1999, 20, 799-804.	1.3	20
176	5-Hydroxy-4-oxo-L-norvaline Depletes Intracellular Glutathione: a New Modulator of Drug Resistance. <i>Bioscience, Biotechnology and Biochemistry</i> , 1999, 63, 1953-1958.	0.6	4
177	Activation of human O6-methylguanine-DNA methyltransferase gene by glucocorticoid hormone. <i>Oncogene</i> , 1999, 18, 525-532.	2.6	66
178	Mice defective in the DNA mismatch gene PMS2 are hypersensitive to MNU induced thymic lymphoma and are partially protected by transgenic expression of human MGMT. <i>Oncogene</i> , 1999, 18, 4394-4400.	2.6	40
179	Influence of O6-benzylguanine on the anti-tumour activity and normal tissue toxicity of 1,3-bis(2-chloroethyl)-1-nitrosourea and molecular combinations of 5-fluorouracil and 2-chloroethyl-1-nitrosourea in mice. <i>British Journal of Cancer</i> , 1999, 79, 1332-1339.	2.9	4
180	Methionine reduces spontaneous and alkylation-induced mutagenesis in <i>Saccharomyces cerevisiae</i> cells deficient in O6-methylguanine-DNA methyltransferase. <i>Mutation Research - Fundamental and Molecular Mechanisms of Mutagenesis</i> , 1999, 430, 99-107.	0.4	6

#	ARTICLE	IF	CITATIONS
181	Methylation of selected CpGs in the human O6-methylguanine-DNA methyltransferase promoter region as a marker of gene silencing. <i>Molecular Carcinogenesis</i> , 1999, 24, 85-89.	1.3	54
182	Activity of O6-methylguanine-DNA methyltransferase in relation to p53 status and therapeutic response in ovarian cancer. , 1999, 84, 388-395.		44
183	A study of ENU-induced mutagenesis in the mouse using the restriction site mutation (RSM) assay. <i>Teratogenesis, Carcinogenesis, and Mutagenesis</i> , 1999, 19, 281-292.	0.8	4
184	Chemotherapy for Adults with Malignant Glioma. <i>Cancer Investigation</i> , 1999, 17, 264-272.	0.6	17
185	Temozolomide in adult patients with advanced soft tissue sarcoma: a phase II study of the EORTC Soft Tissue and Bone Sarcoma Group. <i>European Journal of Cancer</i> , 1999, 35, 410-412.	1.3	67
186	Increased Sensitivity of Human Colon Cancer Cells to DNA Cross-Linking Agents after GRP78 Up-Regulation. <i>Biochemical and Biophysical Research Communications</i> , 1999, 257, 361-368.	1.0	48
187	O6-(4-bromothienyl)guanine improves the therapeutic index of temozolomide against A375M melanoma xenografts. , 2000, 85, 248-252.		35
188	DNA repair and gene therapy: Implications for translational uses. , 2000, 35, 71-81.		32
189	O6-methylguanine formation, repair protein depletion and clinical outcome with a 4 hr schedule of temozolomide in the treatment of advanced melanoma: Results of a phase II study. <i>International Journal of Cancer</i> , 2000, 88, 469-473.	2.3	66
190	Real-Time Fluorescence Assay for O6-Alkylguanine-DNA Alkyltransferase. <i>Analytical Biochemistry</i> , 2000, 281, 216-222.	1.1	31
191	Overexpression of enzymes that repair endogenous damage to DNA. <i>FEBS Journal</i> , 2000, 267, 2135-2149.	0.2	97
192	Protection against Malignant Progression of Spontaneously Developing Liver Tumors in Transgenic Mice Expressing O6-Methylguanine-DNA Methyltransferase. <i>Japanese Journal of Cancer Research</i> , 2000, 91, 1085-1089.	1.7	22
193	Different Mutation Frequencies and Spectra among Organs by N-Methyl-N-nitrosourea in rpsL(strA) Transgenic Mice. <i>Japanese Journal of Cancer Research</i> , 2000, 91, 482-491.	1.7	13
194	Expression of multidrug resistance-associated protein (MRP) in human gliomas. <i>Journal of Neuro-Oncology</i> , 2000, 49, 105-115.	1.4	63
195	Antitumor effect of sarcnu in a O6-methylguanine-DNA methyltransferase positive human glioma xenograft model. <i>Chinese Journal of Cancer Research: Official Journal of China Anti-Cancer Association</i> , Beijing Institute for Cancer Research, 2000, 12, 1-4.	0.7	1
196	Phase I Trial of Carmustine Plus O6-Benzylguanine for Patients With Recurrent or Progressive Malignant Glioma. <i>Journal of Clinical Oncology</i> , 2000, 18, 3522-3528.	0.8	125
197	O6-(Fluorobenzyl)Guanine and Chloroethylnitrosourea in Xenografted Rat Brain Tumor In Vivo. <i>Acta Oncologica</i> , 2000, 39, 89-95.	0.8	0
198	DNA adducts in relation to lung tumour outcome are not markers of susceptibility following a single dose treatment of SWR, BALB/c and C57BL/6j mice with N-nitrosodiethylamine. <i>Biomarkers</i> , 2000, 5, 323-340.	0.9	9

#	ARTICLE	IF	CITATIONS
199	In vivo administration of O6-benzylguanine does not influence apoptosis or mutation frequency following DNA damage in the murine intestine, but does inhibit P450-dependent activation of dacarbazine. <i>Carcinogenesis</i> , 2000, 21, 593-598.	1.3	10
200	Thresholds for Genotoxic Carcinogens. <i>Toxicologic Pathology</i> , 2000, 28, 375-381.	0.9	18
201	Unmasking a killer: DNA O6-methylguanine and the cytotoxicity of methylating agents. <i>Mutation Research - Reviews in Mutation Research</i> , 2000, 462, 71-82.	2.4	168
202	Repair of O6-alkylguanine by alkyltransferases. <i>Mutation Research - Reviews in Mutation Research</i> , 2000, 462, 83-100.	2.4	494
203	DNA repair: counteragent in mutagenesis and carcinogenesis " accomplice in cancer therapy resistance. <i>Mutation Research - Reviews in Mutation Research</i> , 2000, 462, 101-105.	2.4	21
204	Gene transfer to suppress bone marrow alkylation sensitivity. <i>Mutation Research - Reviews in Mutation Research</i> , 2000, 462, 107-120.	2.4	18
205	Repair of O6-methylguanine is not affected by thymine base pairing and the presence of MMR proteins. <i>Mutation Research DNA Repair</i> , 2001, 487, 59-66.	3.8	21
206	The role of nucleotide excision repair and loss of p53 in mutagenesis and carcinogenesis. <i>Toxicology Letters</i> , 2001, 120, 209-219.	0.4	24
207	Anticancer drug resistance in primary human brain tumors. <i>Brain Research Reviews</i> , 2001, 35, 161-204.	9.1	126
208	MGMT Expression in Murine Bone Marrow Is a Major Determinant of Animal Survival After Alkylating Agent Exposure. <i>Journal of Hematotherapy and Stem Cell Research</i> , 2001, 10, 115-123.	1.8	18
210	Methylation and colorectal cancer. <i>Journal of Pathology</i> , 2001, 195, 111-134.	2.1	122
211	Circadian variation in O6-alkylguanine-DNA alkyltransferase activity in circulating blood mononuclear cells of healthy human subjects. <i>International Journal of Cancer</i> , 2001, 91, 60-66.	2.3	20
212	Acquired resistance of melanoma cells to the antineoplastic agent fotemustine is caused by reactivation of the DNA repair gene mgmt. <i>International Journal of Cancer</i> , 2001, 92, 123-129.	2.3	82
213	Inactivation of O6-methylguanine-DNA methyltransferase by glucose-conjugated inhibitors. <i>International Journal of Cancer</i> , 2001, 93, 373-379.	2.3	30
214	Bcl-2 overexpression decreases BCNU sensitivity of a human glioblastoma line through enhancement of catalase activity. <i>Journal of Cellular Biochemistry</i> , 2001, 83, 473-483.	1.2	14
215	Excellent response to gemcitabine in a massively pre-treated woman with extensive cutaneous involvement after recurrence of breast cancer. , 2001, 19, 93-100.		3
216	Antitumor efficacy of SarCNU in a human glioma xenograft model expressing both MGMT and extraneuronal monoamine transporter. <i>Journal of Neuro-Oncology</i> , 2001, 51, 19-24.	1.4	6
217	Overexpression of human O6-alkylguanine DNA alkyltransferase (AGT) prevents MNU induced lymphomas in heterozygous p53 deficient mice. <i>Oncogene</i> , 2001, 20, 5258-5263.	2.6	30

#	ARTICLE	IF	CITATIONS
218	Protection of hematopoietic cells from O <sup>6</sup> -alkylation damage by O <sup>6</sup> -methylguanine DNA methyltransferase gene transfer: studies with different O <sup>6</sup> -alkylating agents and retroviral backbones. <i>European Journal of Haematology</i> , 2001, 67, 2-13.	1.1	20
219	Genetic alterations and chemotherapeutic response in human diffuse gliomas. <i>Expert Review of Anticancer Therapy</i> , 2001, 1, 595-605.	1.1	21
220	1,2-Dimethylhydrazine-Induced Colon Carcinoma and Lymphoma in msh2 <sup>-/-</sup> Mice. <i>Journal of the National Cancer Institute</i> , 2001, 93, 1534-1540.	3.0	45
221	The Modified Human DNA Repair Enzyme O <sup>6</sup> -Methylguanine-DNA Methyltransferase Is a Negative Regulator of Estrogen Receptor-Mediated Transcription upon Alkylation DNA Damage. <i>Molecular and Cellular Biology</i> , 2001, 21, 7105-7114.	1.1	60
222	Human cytidine deaminase as an ex vivo drug selectable marker in gene-modified primary bone marrow stromal cells. <i>Gene Therapy</i> , 2002, 9, 452-462.	2.3	35
223	Phase II Trial of Carmustine Plus O <sup>6</sup> -Benzylguanine for Patients With Nitrosourea-Resistant Recurrent or Progressive Malignant Glioma. <i>Journal of Clinical Oncology</i> , 2002, 20, 2277-2283.	0.8	178
224	Analysis of O <sup>6</sup> -methylguanine-DNA methyltransferase in melanoma tumours in patients treated with dacarbazine-based chemotherapy. <i>Melanoma Research</i> , 2002, 12, 335-342.	0.6	20
225	Simultaneous N <sup>7</sup> ,O <sup>6</sup> -Binding of Guanine to Two Zinc Centers and Its Possible Biological Significance. <i>Inorganic Chemistry</i> , 2002, 41, 4976-4977.	1.9	23
226	Emerging concepts in colorectal neoplasia. <i>Gastroenterology</i> , 2002, 123, 862-876.	0.6	444
228	Inactivation of O <sup>6</sup> -methylguanine-DNA methyltransferase by promoter CpG island hypermethylation in gastric cancers. <i>British Journal of Cancer</i> , 2002, 86, 1888-1892.	2.9	51
229	Polymorphisms of the DNA repair gene XPD and risk of lung cancer in a Chinese population. <i>Lung Cancer</i> , 2002, 38, 123-129.	0.9	83
230	Genotoxicity of Streptozotocin. <i>Mutation Research - Reviews in Mutation Research</i> , 2002, 512, 121-134.	2.4	305
231	Smoking-related increase of O <sup>6</sup> -methylguanine-DNA methyltransferase expression in squamous cell carcinoma of the esophagus. <i>Cancer Letters</i> , 2002, 184, 49-55.	3.2	21
232	Chemotherapy for Malignant Gliomas. <i>Japanese Journal of Neurosurgery</i> , 2002, 11, 347-354.	0.0	0
233	DNA adducts and liver DNA replication in rats during chronic exposure to N-nitrosodimethylamine (NDMA) and their relationships to the dose-dependence of NDMA hepatocarcinogenesis. <i>Mutation Research - Fundamental and Molecular Mechanisms of Mutagenesis</i> , 2002, 500, 75-87.	0.4	33
234	Chromosomal response of human lymphocytes to streptozotocin. <i>Mutation Research - Fundamental and Molecular Mechanisms of Mutagenesis</i> , 2002, 503, 63-68.	0.4	8
235	Polymorphisms in DNA repair and environmental interactions. <i>Mutation Research - Fundamental and Molecular Mechanisms of Mutagenesis</i> , 2002, 509, 201-210.	0.4	70
236	Biochemical changes associated with a multidrug-resistant phenotype of a human glioma cell line with temozolomide-acquired resistance. <i>Biochemical Pharmacology</i> , 2002, 63, 1219-1228.	2.0	51

#	ARTICLE	IF	CITATIONS
237	In vitro pharmacokinetics and pharmacodynamics of 1,3-bis(2-chloroethyl)-1-nitrosourea (BCNU). <i>Biochemical Pharmacology</i> , 2002, 63, 1209-1218.	2.0	33
238	Synthesis of radiolabeled O6-benzylguanine derivatives as new potential PET tumor imaging agents for the DNA repair protein O6-alkylguanine-DNA alkyltransferase. <i>Journal of Labelled Compounds and Radiopharmaceuticals</i> , 2002, 45, 1239-1252.	0.5	15
239	Effect of O6-(4-bromothienyl)guanine on different temozolomide schedules in a human melanoma xenograft model. <i>International Journal of Cancer</i> , 2002, 100, 615-617.	2.3	43
240	Deficient expression of O6-Methylguanine-DNA methyltransferase combined with mismatch-repair proteins hMLH1 and hMSH2 is related to poor prognosis in human biliary tract carcinoma. <i>Annals of Surgical Oncology</i> , 2002, 9, 371-379.	0.7	52
241	An approach to the evaluation of the activity of the DNA repair enzyme O6-methylguanine-DNA-methyl-transferase in tumor tissue in vivo: syntheses of 6-benzyloxy-9-(2-[18F]fluoroethyl)-9H-purin-2-yl-amine and 6-benzyloxy-7-(2-[18F]fluoroethyl)-7H-purin-2-yl-amine. <i>Applied Radiation and Isotopes</i> , 2002, 56, 511-517.	0.7	8
242	Inactivation of O6-Methylguanine-DNA Methyltransferase in Human Lung Adenocarcinoma Relates to High-grade Histology and Worse Prognosis among Smokers. <i>Japanese Journal of Cancer Research</i> , 2002, 93, 184-189.	1.7	24
243	Heterogeneity of O6-alkylguanine DNA-alkyltransferase expression in human breast tumours. <i>British Journal of Cancer</i> , 2002, 86, 1797-1802.	2.9	15
244	The Sensitivity of MCF10A Breast Epithelial Cells to Alkylating Drugs is Enhanced by the Inhibition of O6-Methylguanine-DNA Methyltransferase Transcription with a Synthetic Double Strand DNA Oligonucleotide. <i>Breast Cancer Research and Treatment</i> , 2002, 73, 207-213.	1.1	3
245	Role of excision mechanisms of DNA repair in induction of apoptosis. <i>Biochemistry (Moscow)</i> , 2002, 67, 730-736.	0.7	8
246	Current developments in the design of onco-retrovirus and lentivirus vector systems for hematopoietic cell gene therapy. <i>Biochimica Et Biophysica Acta - Molecular Cell Research</i> , 2003, 1640, 1-24.	1.9	57
247	Coffee and its chemopreventive components Kahweol and Cafestol increase the activity of O6-methylguanine-DNA methyltransferase in rat liver—comparison with phase II xenobiotic metabolism. <i>Mutation Research - Fundamental and Molecular Mechanisms of Mutagenesis</i> , 2003, 522, 57-68.	0.4	73
248	Pharmacokinetic, biochemical and clinical effects of dimethyltriazenoimidazole-4-carboxamide-bis(2-chloroethyl)nitrosourea combination therapy in patients with advanced breast cancer. <i>International Journal of Cancer</i> , 2003, 103, 686-692.	2.3	5
249	Combined loss of expression of O6-methylguanine-DNA methyltransferase and hMLH1 accelerates progression of hepatocellular carcinoma. <i>Journal of Surgical Oncology</i> , 2003, 82, 194-200.	0.8	20
250	DNA repair gene O6-methylguanine-DNA methyltransferase: Promoter hypermethylation associated with decreased expression and G:C to A:T mutations of p53 in brain tumors. <i>Molecular Carcinogenesis</i> , 2003, 36, 23-31.	1.3	47
251	Alteration of O6-methylguanine-DNA methyltransferase in colorectal neoplasms in sporadic and familial adenomatous polyposis patients. <i>Molecular Carcinogenesis</i> , 2003, 37, 32-38.	1.3	11
252	How Do DNA Repair Proteins Locate Potential Base Lesions? A Chemical Crosslinking Method to Investigate O6-Alkylguanine-DNA Alkyltransferases. <i>Chemistry and Biology</i> , 2003, 10, 827-835.	6.2	28
253	Synthesis and preliminary biological evaluation of 6-O-[11C]-[(methoxymethyl)benzyl]guanines, new potential PET breast cancer imaging agents for the DNA repair protein AGT. <i>Biorganic and Medicinal Chemistry Letters</i> , 2003, 13, 641-644.	1.0	15
254	Marked inactivation of O6-alkylguanine-DNA alkyltransferase activity with protracted temozolomide schedules. <i>British Journal of Cancer</i> , 2003, 88, 1004-1011.	2.9	347

#	ARTICLE	IF	CITATIONS
255	A single amino acid substitution in MSH5 results in DNA alkylation tolerance. <i>Gene</i> , 2003, 315, 177-182.	1.0	14
256	Improvement of chemotherapy efficacy by inactivation of a DNA-repair pathway. <i>Lancet Oncology</i> , The, 2003, 4, 37-44.	5.1	105
257	Hypersensitivity of DNA polymerase $\beta$ null mouse fibroblasts reflects accumulation of cytotoxic repair intermediates from site-specific alkyl DNA lesions. <i>DNA Repair</i> , 2003, 2, 27-48.	1.3	88
258	Synthesis and preliminary biological evaluation of radiolabeled O6-benzylguanine derivatives, new potential PET imaging agents for the DNA repair protein O6-alkylguanine-DNA alkyltransferase in breast cancer. <i>Nuclear Medicine and Biology</i> , 2003, 30, 405-415.	0.3	38
259	The Effect of O6-Alkylguanine-DNA Alkyltransferase and Mismatch Repair Activities on the Sensitivity of Human Melanoma Cells to Temozolomide, 1,3-bis(2-Chloroethyl)-1-nitrosourea, and Cisplatin. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2003, 304, 661-668.	1.3	77
260	Cytotoxicity, DNA Damage, and Apoptosis Induced by New Fotemustine Analogs on Human Melanoma Cells in Relation to O6-Methylguanine DNA-Methyltransferase Expression. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2003, 307, 816-823.	1.3	29
261	CpG methylation of MGMT and hMLH1 promoter in hepatocellular carcinoma associated with hepatitis viral infection. <i>British Journal of Cancer</i> , 2003, 88, 521-529.	2.9	56
262	O6-methylguanine-DNA-methyltransferase expression and gene polymorphisms in relation to chemotherapeutic response in metastatic melanoma. <i>British Journal of Cancer</i> , 2003, 89, 1517-1523.	2.9	65
263	The p38 Mitogen-Activated Protein Kinase Pathway Links the DNA Mismatch Repair System to the G2 Checkpoint and to Resistance to Chemotherapeutic DNA-Methylating Agents. <i>Molecular and Cellular Biology</i> , 2003, 23, 8306-8315.	1.1	125
264	Molecular Analysis of Therapy Resistance in Gastric Cancer. <i>Digestive Diseases</i> , 2003, 21, 326-338.	0.8	29
265	Pharmacokinetics of O6-Benzylguanine (NSC637037) and Its Metabolite, 8-Oxo-O6-Benzylguanine. <i>Journal of Clinical Pharmacology</i> , 2003, 43, 881-893.	1.0	16
266	Pharmacokinetics of O6-benzylguanine in Pediatric Patients with Central Nervous System Tumors. <i>Clinical Cancer Research</i> , 2004, 10, 5072-5075.	3.2	11
267	Differential Methylation Status of Tumor-Associated Genes in Head and Neck Squamous Carcinoma. <i>Clinical Cancer Research</i> , 2004, 10, 3825-3830.	3.2	140
268	A Randomized Phase I and Pharmacological Trial of Sequences of 1,3-bis(2-Chloroethyl)-1-Nitrosourea and Temozolomide in Patients with Advanced Solid Neoplasms. <i>Clinical Cancer Research</i> , 2004, 10, 1645-1656.	3.2	30
269	Generating mutations but providing chemosensitivity: the role of O6-methylguanine DNA methyltransferase in human cancer. <i>Oncogene</i> , 2004, 23, 1-8.	2.6	289
270	Intra- and intercellular variations in the repair efficiency of O6-methylguanine, and their contribution to kinetic complexity. <i>Mutation Research - Fundamental and Molecular Mechanisms of Mutagenesis</i> , 2004, 568, 155-170.	0.4	11
271	Aberrant CpG Island Methylation of Multiple Genes in Ependymal Tumors. <i>Journal of Neuro-Oncology</i> , 2004, 67, 159-165.	1.4	38
272	DNA methylation of multiple promoter-associated CpG islands in meningiomas: relationship with the allelic status at 1p and 22q. <i>Acta Neuropathologica</i> , 2004, 108, 413-421.	3.9	63



#	ARTICLE	IF	CITATIONS
273	1,2-Bis(methylsulfonyl)-1-(2-chloroethyl)-2-[(methylamino)carbonyl]hydrazine (VNP40101M): II. Role of O <sup>6</sup> -alkylguanine-DNA alkyltransferase in cytotoxicity. <i>Cancer Chemotherapy and Pharmacology</i> , 2004, 53, 288-295.	1.1	33
274	Clinical value of molecular changes in ovarian carcinoma. <i>Reports of Practical Oncology and Radiotherapy</i> , 2004, 9, 149-155.	0.3	0
275	A CpG island hypermethylation profile of primary colorectal carcinomas and colon cancer cell lines. <i>Molecular Cancer</i> , 2004, 3, 28.	7.9	140
276	Killing and mutagenic actions of dacarbazine, a chemotherapeutic alkylating agent, on human and mouse cells: effects of Mgmt and Mlh1 mutations. <i>DNA Repair</i> , 2004, 3, 413-420.	1.3	40
277	Procarbazine in haematology: an old drug with a new life?. <i>European Journal of Cancer</i> , 2004, 40, 1924-1927.	1.3	23
278	Synthesis and preliminary biological evaluation of O <sup>6</sup> -[4-(2-[ <sup>18</sup> F]fluoroethoxymethyl)benzyl]guanine as a novel potential PET probe for the DNA repair protein O <sup>6</sup> -alkylguanine-DNA alkyltransferase in cancer chemotherapy. <i>Bioorganic and Medicinal Chemistry</i> , 2005, 13, 5779-5786.	1.4	4
279	Temozolomide in the treatment of solid tumours: current results and rationale for dosing/scheduling. <i>Critical Reviews in Oncology/Hematology</i> , 2005, 53, 241-252.	2.0	53
280	Tumor Progression Through Epigenetic Gene Silencing of O <sup>6</sup> -Methylguanine-DNA Methyltransferase in Human Biliary Tract Cancers. <i>Annals of Surgical Oncology</i> , 2005, 12, 354-363.	0.7	53
281	O <sup>6</sup> -(4-bromothienyl)guanine reverses temozolomide resistance in human breast tumour MCF-7 cells and xenografts. <i>British Journal of Cancer</i> , 2005, 93, 1152-1156.	2.9	52
282	Inactivated MGMT by O <sup>6</sup> -Benzylguanine is associated with prolonged G2/M arrest in cancer cells treated with BCNU. <i>Oncogene</i> , 2005, 24, 2175-2183.	2.6	35
283	Role of O <sup>6</sup> -methylguanine-DNA methyltransferase and effect of O <sup>6</sup> -benzylguanine on the anti-tumor activity of cis-diaminedichloroplatinum(II) in oral cancer cell lines. <i>Oral Oncology</i> , 2005, 41, 984-993.	0.8	14
284	Aberrant methylation and loss of expression of O <sup>6</sup> -methylguanine-DNA methyltransferase in pulmonary squamous cell carcinoma and adenocarcinoma. <i>Pathology International</i> , 2005, 55, 303-309.	0.6	17
285	Polymorphism in folate- and methionine-metabolizing enzyme and aberrant CpG island hypermethylation in uterine cervical cancer. <i>Gynecologic Oncology</i> , 2005, 96, 173-180.	0.6	99
286	Gene expression profile induced by BCNU in human glioma cell lines with differential MGMT expression. <i>Journal of Neuro-Oncology</i> , 2005, 73, 189-198.	1.4	10
287	New Delivery Approaches for Pediatric Brain Tumors. <i>Journal of Neuro-Oncology</i> , 2005, 75, 315-326.	1.4	4
288	Temozolomide in combination with BCNU before and after radiotherapy in patients with inoperable newly diagnosed glioblastoma multiforme. <i>Annals of Oncology</i> , 2005, 16, 1177-1184.	0.6	46
289	Poly(ADP-ribose) polymerase-1 inhibition reverses temozolomide resistance in a DNA mismatch repair-deficient malignant glioma xenograft. <i>Molecular Cancer Therapeutics</i> , 2005, 4, 1364-1368.	1.9	173
290	Role of O <sup>6</sup> -Alkylguanine-DNA Alkyltransferase in Protecting against 1,3-Bis(2-chloroethyl)-1-nitrosourea (BCNU)-Induced Long-Term Toxicities. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2005, 315, 1247-1255.	1.3	10

#	ARTICLE	IF	CITATIONS
291	DNA Methylation, Field Effects, and Colorectal Cancer. <i>Journal of the National Cancer Institute</i> , 2005, 97, 1317-1319.	3.0	71
292	Patients with High-Grade Gliomas Harboring Deletions of Chromosomes 9p and 10q Benefit from Temozolomide Treatment. <i>Neoplasia</i> , 2005, 7, 883-893.	2.3	55
294	The Structure of the Human AGT Protein Bound to DNA and its Implications for Damage Detection. <i>Journal of Molecular Biology</i> , 2005, 350, 657-666.	2.0	87
295	Chemotherapeutic agents for colorectal cancer with a defective mismatch repair system: The state of the art. <i>Cancer Treatment Reviews</i> , 2006, 32, 607-618.	3.4	29
296	DNA hypermethylation status of multiple genes in soft tissue sarcomas. <i>Modern Pathology</i> , 2006, 19, 106-114.	2.9	55
297	Direct Reversal of DNA Alkylation Damage. <i>Chemical Reviews</i> , 2006, 106, 215-232.	23.0	193
298	O6-Methylguanine-DNA Methyltransferase Leu84Phe and Ile143Val Polymorphisms and Risk of Colorectal Cancer in the Nurses' Health Study and Physicians' Health Study (United States). <i>Cancer Causes and Control</i> , 2006, 17, 721-731.	0.8	39
299	Aberrant promoter hypermethylation in biliary tract carcinoma. <i>Journal of Hepato-Biliary-Pancreatic Surgery</i> , 2006, 13, 296-305.	2.0	7
300	Syntheses of O6-Alkyl- and Arylguanine Derivatives: Nucleobase Adducts Derived from Styrene 7,8- and 3,4-Oxides. <i>European Journal of Organic Chemistry</i> , 2006, 2006, 507-515.	1.2	5
301	Quantitative analysis of promoter hypermethylation in multiple genes in osteosarcoma. <i>Cancer</i> , 2006, 106, 1602-1609.	2.0	51
302	Modulation of chemotherapy resistance in regional therapy: a novel therapeutic approach to advanced extremity melanoma using intra-arterial temozolomide in combination with systemic O6-benzylguanine. <i>Molecular Cancer Therapeutics</i> , 2006, 5, 732-738.	1.9	43
303	Quantitative analysis of O6-alkylguanine-DNA alkyltransferase in malignant glioma. <i>Molecular Cancer Therapeutics</i> , 2006, 5, 2531-2539.	1.9	82
304	In vitro Drug Response and Molecular Markers Associated with Drug Resistance in Malignant Gliomas. <i>Clinical Cancer Research</i> , 2006, 12, 4523-4532.	3.2	72
305	Interactions of Human O6-Alkylguanine-DNA Alkyltransferase (AGT) with Short Single-stranded DNAs. <i>Journal of Biological Chemistry</i> , 2007, 282, 3357-3366.	1.6	40
306	Mutator pathways unleashed by epigenetic silencing in human cancer. <i>Mutagenesis</i> , 2007, 22, 247-253.	1.0	123
307	The human checkpoint sensor Rad9/Rad1/Hus1 interacts with and stimulates DNA repair enzyme TDG glycosylase. <i>Nucleic Acids Research</i> , 2007, 35, 6207-6218.	6.5	57
308	Prostate Cancer Epigenetics: A Review on Gene Regulation. <i>Gene Regulation and Systems Biology</i> , 2007, 1, GR5B.S398.	2.3	11
309	Targeting DNA repair as a promising approach in cancer therapy. <i>European Journal of Cancer</i> , 2007, 43, 1791-1801.	1.3	89

#	ARTICLE	IF	CITATIONS
310	Nitric oxide donors attenuate clonogenic potential in rat C6 glioma cells treated with alkylating chemotherapeutic agents. <i>Neuroscience Letters</i> , 2007, 418, 106-110.	1.0	9
311	The therapeutic potential of <i>O</i> <sup>6</sup> -alkylguanine DNA alkyltransferase inhibitors. <i>Expert Opinion on Investigational Drugs</i> , 2007, 16, 1573-1584.	1.9	36
312	Therapeutic potential of drugs to modulate DNA repair in cancer. <i>Expert Opinion on Therapeutic Targets</i> , 2007, 11, 783-799.	1.5	28
313	Genetic variants in MGMT and risk of lung cancer in Southeastern Chinese: a haplotype-based analysis. <i>Human Mutation</i> , 2007, 28, 431-440.	1.1	46
314	Differential DNA methylation associated with hepatitis B virus infection in hepatocellular carcinoma. <i>International Journal of Cancer</i> , 2007, 121, 1257-1264.	2.3	81
315	Tamoxifen accelerates proteasomal degradation of <i>O</i> <sup>6</sup> -methylguanine DNA methyltransferase in human cancer cells. <i>International Journal of Cancer</i> , 2007, 121, 2293-2300.	2.3	23
316	Unusually marked hypoxic sensitization to indoloquinone E09 and mitomycin C in a human colon tumour cell line that lacks DT diaphorase activity. <i>International Journal of Cancer</i> , 1994, 56, 134-139.	2.3	61
317	Curcumin suppresses growth and chemoresistance of human glioblastoma cells via AP-1 and NF $\kappa$ B transcription factors. <i>Journal of Neurochemistry</i> , 2007, 102, 522-538.	2.1	267
318	Role of MGMT in protecting against cyclophosphamide-induced toxicity in cells and animals. <i>DNA Repair</i> , 2007, 6, 1145-1154.	1.3	20
319	MGMT hypermethylation: A prognostic foe, a predictive friend. <i>DNA Repair</i> , 2007, 6, 1155-1160.	1.3	138
320	Interindividual differences in anticancer drug cytotoxicity in primary human glioblastoma cells. <i>Experimental and Toxicologic Pathology</i> , 2007, 58, 247-253.	2.1	10
321	MGMT expression in oral precancerous and cancerous lesions: Correlation with progression, nodal metastasis and poor prognosis. <i>Oral Oncology</i> , 2007, 43, 515-522.	0.8	33
322	The Fanconi anemia (FA) pathway confers glioma resistance to DNA alkylating agents. <i>Journal of Molecular Medicine</i> , 2007, 85, 497-509.	1.7	74
323	<i>O</i> <sup>6</sup> -benzylguanine and BCNU in multiple myeloma: a phase II trial. <i>Cancer Chemotherapy and Pharmacology</i> , 2007, 60, 415-421.	1.1	25
324	Toxicity and efficacy of protracted low dose temozolomide for the treatment of low grade gliomas. <i>Journal of Neuro-Oncology</i> , 2007, 82, 281-288.	1.4	79
326	Variation of <i>O</i> <sup>6</sup> -methylguanine-DNA methyltransferase (MGMT) promoter methylation in serial samples in glioblastoma. <i>Journal of Neuro-Oncology</i> , 2008, 87, 71-78.	1.4	86
327	The effect of the aqueous extract of the roots of <i>Asparagus racemosus</i> on hepatocarcinogenesis initiated by diethylnitrosamine. <i>Phytotherapy Research</i> , 2008, 22, 1175-1182.	2.8	31
328	Phase 1 trial of <i>O</i> <sup>6</sup> -benzylguanine and BCNU in children with CNS tumors: A Children's Oncology Group study. <i>Pediatric Blood and Cancer</i> , 2008, 50, 549-553.	0.8	18

#	ARTICLE	IF	CITATIONS
329	Methylation pattern of the O <sup>6</sup> -methylguanine-DNA methyltransferase gene in colon during progressive colorectal tumorigenesis. <i>International Journal of Cancer</i> , 2008, 122, 2429-2436.	2.3	62
330	Diazirine-Based DNA Photo-Cross-Linking Probes for the Study of Protein-DNA Interactions. <i>Angewandte Chemie - International Edition</i> , 2008, 47, 90-93.	7.2	67
332	A methylation-specific and SYBR-green-based quantitative polymerase chain reaction technique for O <sup>6</sup> -methylguanine DNA methyltransferase promoter methylation analysis. <i>Analytical Biochemistry</i> , 2008, 377, 62-71.	1.1	57
333	The Involvement of Mismatch Repair in Transcription Coupled Nucleotide Excision Repair. <i>Human Cell</i> , 2005, 18, 103-115.	1.2	9
334	A phase II trial of lomeguatrib and temozolomide in metastatic colorectal cancer. <i>British Journal of Cancer</i> , 2008, 98, 1614-1618.	2.9	49
335	Alterations in S-adenosylhomocysteine metabolism decrease O <sup>6</sup> -methylguanine DNA methyltransferase gene expression without affecting promoter methylation. <i>Biochemical Pharmacology</i> , 2008, 75, 2100-2111.	2.0	11
336	Epigenetic drivers and genetic passengers on the road to cancer. <i>Mutation Research - Fundamental and Molecular Mechanisms of Mutagenesis</i> , 2008, 642, 1-13.	0.4	137
337	Contribution of DNA repair mechanisms to determining chemotherapy response in high-grade glioma. <i>Journal of Clinical Neuroscience</i> , 2008, 15, 1-8.	0.8	21
338	Mismatch Repair Deficiency Does Not Mediate Clinical Resistance to Temozolomide in Malignant Glioma. <i>Clinical Cancer Research</i> , 2008, 14, 4859-4868.	3.2	67
339	Interactions of Human O <sup>6</sup> -Alkylguanine-DNA Alkyltransferase (AGT) with Short Double-Stranded DNAs. <i>Biochemistry</i> , 2008, 47, 13754-13763.	1.2	30
340	<i>In vitro</i> and <i>In vivo</i> Radiosensitization Induced by the DNA Methylating Agent Temozolomide. <i>Clinical Cancer Research</i> , 2008, 14, 931-938.	3.2	104
341	Genomic predictors of interindividual differences in response to DNA damaging agents. <i>Genes and Development</i> , 2008, 22, 2621-2626.	2.7	59
342	Transcriptional Repression of O <sup>6</sup> -Methylguanine DNA Methyltransferase Gene Rendering Cells Hypersensitive to N,N-Bis(2-chloroethyl)-N-nitrosourea in Camptothecin-Resistant Cells. <i>Molecular Pharmacology</i> , 2008, 74, 517-526.	1.0	6
343	Frequency and Spectrum of lacI Mutations in the Liver of Big Blue Mice Following the Administration of Genotoxic Carcinogens Singly and in Series. <i>International Journal of Toxicology</i> , 2008, 27, 35-42.	0.6	7
344	Inhibition of DNA repair as a therapeutic target. , 2008, , 284-304.		0
345	Low susceptibility to N-ethyl-N-nitrosourea-induced transplacental carcinogenesis in Long-Evans Cinnamon (LEC) rats. <i>Journal of Medical Investigation</i> , 2009, 56, 93-98.	0.2	0
346	O <sup>6</sup> -methylguanine-induced cell death involves exonuclease 1 as well as DNA mismatch recognition in vivo. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2009, 106, 576-581.	3.3	49
347	Detection of Methylation in the CpG islands of the P16INK4A, RASSF 1A and Methyl-Guanine Methyl-Transferase (MGMT) gene promoters in Pancreatic Adenocarcinoma. <i>Ecancermedicalscience</i> , 2009, 3, 131.	0.6	0

#	ARTICLE	IF	CITATIONS
348	Correlation among pathology, genetic and epigenetic profiles, and clinical outcome in oligodendroglial tumors. <i>International Journal of Cancer</i> , 2009, 124, 2872-2879.	2.3	32
349	Influence of <i>Helicobacter pylori</i> infection on the expression of MLH1 and MGMT in patients with chronic gastritis and gastric cancer. <i>European Journal of Clinical Microbiology and Infectious Diseases</i> , 2009, 28, 591-597.	1.3	7
350	Methylguanine DNA Methyltransferase-Mediated Drug Resistance-Based Selective Enrichment and Engraftment of Transplanted Stem Cells in Skeletal Muscle. <i>Stem Cells</i> , 2009, 27, 1098-1108.	1.4	7
351	Experimental mouse models for hepatocellular carcinoma research. <i>International Journal of Experimental Pathology</i> , 2009, 90, 367-386.	0.6	314
352	Cancer epigenomics: Implications of DNA methylation in personalized cancer therapy. <i>Cancer Science</i> , 2009, 100, 787-791.	1.7	85
353	Methylation status of the MGMT gene promoter fails to predict the clinical outcome of glioblastoma patients treated with ACNU plus cisplatin. <i>Neuropathology</i> , 2009, 29, 443-449.	0.7	37
354	Targeting DNA repair pathways: A novel approach to reduce cancer therapeutic resistance. <i>Cancer Treatment Reviews</i> , 2009, 35, 590-596.	3.4	51
355	Topologies of Complexes Containing O6-Alkylguanine-DNA Alkyltransferase and DNA. <i>Journal of Molecular Biology</i> , 2009, 389, 248-263.	2.0	30
356	Genomic and Molecular Profiling Predicts Response to Temozolomide in Melanoma. <i>Clinical Cancer Research</i> , 2009, 15, 502-510.	3.2	89
357	Aberrant methylation of tumour-related genes in thymic epithelial tumours. <i>Lung Cancer</i> , 2009, 64, 155-159.	0.9	30
358	Combination of Intracranial Temozolomide With Intracranial Carmustine Improves Survival When Compared With Either Treatment Alone in a Rodent Glioma Model. <i>Neurosurgery</i> , 2010, 66, 530-537.	0.6	57
359	MGMT G535G>T polymorphism is associated with prognosis for patients with metastatic colorectal cancer treated with oxaliplatin-based chemotherapy. <i>Journal of Cancer Research and Clinical Oncology</i> , 2010, 136, 1135-1142.	1.2	26
360	DNA hypermethylation markers of poor outcome in laryngeal cancer. <i>Clinical Epigenetics</i> , 2010, 1, 61-69.	1.8	28
361	DNA repair pathways and their implication in cancer treatment. <i>Cancer and Metastasis Reviews</i> , 2010, 29, 677-685.	2.7	28
362	Novel approaches to global mining of aberrantly methylated promoter sites in squamous head and neck cancer. <i>Otolaryngology - Head and Neck Surgery</i> , 2010, 143, 116.	1.1	6
363	MGMT Ile143Val polymorphism, dietary factors and the risk of breast, colorectal and prostate cancer in the European Prospective Investigation into Cancer and Nutrition (EPIC)-Norfolk study. <i>DNA Repair</i> , 2010, 9, 421-428.	1.3	23
364	MGMT activity, promoter methylation and immunohistochemistry of pretreatment and recurrent malignant gliomas: a comparative study on astrocytoma and glioblastoma. <i>International Journal of Cancer</i> , 2010, 127, 2106-2118.	2.3	97
365	Aberrant methylation of DNA mismatch repair genes in elderly patients with sporadic gastric carcinoma: A comparison with younger patients. <i>Journal of Surgical Oncology</i> , 2010, 101, 28-35.	0.8	29

#	ARTICLE	IF	CITATIONS
366	Chemoprotection of human hematopoietic stem cells by simultaneous lentiviral overexpression of multidrug resistance 1 and O6-methylguanine-DNA methyltransferaseP140K. <i>Gene Therapy</i> , 2010, 17, 389-399.	2.3	45
367	DNA Mismatch Repair in Eukaryotes and Bacteria. <i>Journal of Nucleic Acids</i> , 2010, 2010, 1-16.	0.8	151
368	Development of a Novel Fluorescence Assay Based on the Use of the Thrombin-Binding Aptamer for the Detection ofO6-Alkylguanine-DNA Alkyltransferase Activity. <i>Journal of Nucleic Acids</i> , 2010, 2010, 1-9.	0.8	20
369	Epigenetic Drivers of Genetic Alterations. <i>Advances in Genetics</i> , 2010, 70, 309-323.	0.8	55
370	O6-Methylguanine-DNA methyltransferase expression and prognostic value in brain metastases of lung cancers. <i>Lung Cancer</i> , 2010, 68, 484-490.	0.9	29
371	Incorporating BCNU Wafers into Malignant Glioma Treatment. <i>Clinical Drug Investigation</i> , 2010, 30, 195-204.	1.1	10
372	Quantitative detection of multiple gene promoter hypermethylation in tumor tissue, serum, and cerebrospinal fluid predicts prognosis of malignant gliomas. <i>Neuro-Oncology</i> , 2010, 12, 540-548.	0.6	61
373	Carcinogenic Alkylating Agents*. , 2010, , 63-83.		5
374	Long-term In Vitro Treatment of Human Glioblastoma Cells with Temozolomide Increases Resistance In Vivo through Up-regulation of GLUT Transporter and Aldo-Keto Reductase Enzyme AKR1C Expression. <i>Neoplasia</i> , 2010, 12, 727-739.	2.3	104
375	Role of Histone Modifications and DNA Methylation in the Regulation of O <sup>6</sup> -Methylguanine-DNA Methyltransferase Gene Expression in Human Stomach Cancer Cells. <i>Cancer Investigation</i> , 2010, 28, 331-339.	0.6	21
376	Regional Treatment Strategies for In-Transit Melanoma Metastasis. <i>Surgical Oncology Clinics of North America</i> , 2011, 20, 79-103.	0.6	30
377	4-Nitrobenzyloxycarbonyl Derivatives of O <sup>6</sup> -Benzylguanine as Hypoxia-Activated Prodrug Inhibitors of O <sup>6</sup> -Alkylguanine-DNA Alkyltransferase (AGT), Which Produces Resistance to Agents Targeting the O <sup>6</sup> Position of DNA Guanine. <i>Journal of Medicinal Chemistry</i> , 2011, 54, 7720-7728.	2.9	46
378	Mutations That Probe the Cooperative Assembly of O <sup>6</sup> -Alkylguanine-DNA Alkyltransferase Complexes. <i>Biochemistry</i> , 2011, 50, 1590-1598.	1.2	14
379	Fotemustine for the treatment of melanoma. <i>Expert Opinion on Pharmacotherapy</i> , 2011, 12, 2891-2904.	0.9	24
380	Establishment, Maintenance, and In Vitro and In Vivo Applications of Primary Human Glioblastoma Multiforme (GBM) Xenograft Models for Translational Biology Studies and Drug Discovery. <i>Current Protocols in Pharmacology</i> , 2011, 52, Unit 14.16.	4.0	185
381	O6-methylguanine-DNA methyltransferase (MGMT): Can function explain a suicidal mechanism?. <i>Medical Hypotheses</i> , 2011, 77, 857-860.	0.8	7
382	Recurrent Glioblastoma: A Fresh Look at Current Therapies and Emerging Novel Approaches. <i>Seminars in Oncology</i> , 2011, 38, S21-S33.	0.8	45
383	O6-Methylguanine-DNA methyltransferase (MGMT) in normal tissues and tumors: Enzyme activity, promoter methylation and immunohistochemistry. <i>Biochimica Et Biophysica Acta: Reviews on Cancer</i> , 2011, 1816, 179-190.	3.3	142

#	ARTICLE	IF	CITATIONS
384	Expression of O6-methylguanine-DNA methyltransferase in childhood medulloblastoma. <i>Journal of Neuro-Oncology</i> , 2011, 103, 59-69.	1.4	12
385	Promoter methylation status of hMLH1, hMSH2, and MGMT genes in colorectal cancer associated with adenoma-carcinoma sequence. <i>Langenbeck's Archives of Surgery</i> , 2011, 396, 1017-1026.	0.8	33
386	Promoter hypermethylation of RASSF1A, MGMT, and HIC-1 genes in benign and malignant colorectal tumors. <i>Tumor Biology</i> , 2011, 32, 845-852.	0.8	35
387	Lesion-specific DNA-binding and repair activities of human O6-alkylguanine DNA alkyltransferase. <i>Nucleic Acids Research</i> , 2012, 40, 9060-9072.	6.5	9
388	Mismatch repair deficiency: a temozolomide resistance factor in medulloblastoma cell lines that is uncommon in primary medulloblastoma tumours. <i>British Journal of Cancer</i> , 2012, 107, 1399-1408.	2.9	38
389	F2A sequence linking MGMT140K and MDR1 in a bicistronic lentiviral vector enables efficient chemoprotection of haematopoietic stem cells. <i>Cancer Gene Therapy</i> , 2012, 19, 802-810.	2.2	10
390	Valproic Acid Downregulates the Expression of MGMT and Sensitizes Temozolomide-Resistant Glioma Cells. <i>Journal of Biomedicine and Biotechnology</i> , 2012, 2012, 1-9.	3.0	90
391	Complex DNA repair pathways as possible therapeutic targets to overcome temozolomide resistance in glioblastoma. <i>Frontiers in Oncology</i> , 2012, 2, 186.	1.3	88
392	Cooperative cluster formation, DNA bending and base-flipping by O <sup>6</sup> -alkylguanine-DNA alkyltransferase. <i>Nucleic Acids Research</i> , 2012, 40, 8296-8308.	6.5	24
393	Promoter methylation of MGMT, MLH1 and RASSF1A tumor suppressor genes in head and neck squamous cell carcinoma: Pharmacological genome demethylation reduces proliferation of head and neck squamous carcinoma cells. <i>Oncology Reports</i> , 2012, 27, 1135-1141.	1.2	46
394	DNA repair dysregulation from cancer driver to therapeutic target. <i>Nature Reviews Cancer</i> , 2012, 12, 801-817.	12.8	851
395	Promoter Methylation in Head and Neck Tumorigenesis. <i>Methods in Molecular Biology</i> , 2012, 863, 187-206.	0.4	9
396	Design of a hypoxia-activated prodrug inhibitor of O6-alkylguanine-DNA alkyltransferase. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2012, 22, 6242-6247.	1.0	15
397	O6-methylguanine-DNA methyltransferase (MGMT): impact on cancer risk in response to tobacco smoke. <i>Mutation Research - Fundamental and Molecular Mechanisms of Mutagenesis</i> , 2012, 736, 64-74.	0.4	40
398	O6-methylguanine-DNA methyltransferase in equine sarcoids: molecular and epigenetic analysis. <i>BMC Veterinary Research</i> , 2012, 8, 218.	0.7	8
399	MGMT. , 2012, , 17-28.		3
400	Molecular Characterization of Head and Neck Cancer. <i>Molecular Diagnosis and Therapy</i> , 2012, 16, 209-222.	1.6	22
401	&lt;i>N</i>-Ethyl-&lt;i>N</i>-Nitrosourea Induces Retinal Photoreceptor Damage in Adult Rats. <i>Journal of Toxicologic Pathology</i> , 2012, 25, 27-35.	0.3	14

#	ARTICLE	IF	CITATIONS
402	Functional analyses of human DNA repair proteins important for aging and genomic stability using yeast genetics. <i>DNA Repair</i> , 2012, 11, 335-348.	1.3	12
403	MGMT and PTEN as potential prognostic markers in breast cancer. <i>Experimental and Molecular Pathology</i> , 2012, 92, 20-26.	0.9	17
404	TMZ-induced PrPc/parâ€4 interaction promotes the survival of human glioma cells. <i>International Journal of Cancer</i> , 2012, 130, 309-318.	2.3	26
405	Efficacy of protracted temozolomide dosing is limited in MGMT unmethylated GBM xenograft models. <i>Neuro-Oncology</i> , 2013, 15, 735-746.	0.6	22
406	Breast cancers with high DSS1 expression that potentially maintains BRCA2 stability have poor prognosis in the relapse-free survival. <i>BMC Cancer</i> , 2013, 13, 562.	1.1	16
407	Correlation of chromosome damage and promoter methylation status of the DNA repair genes MGMT and hMLH1 in Chinese vinyl chloride monomer (VCM)-exposed workers. <i>International Journal of Occupational Medicine and Environmental Health</i> , 2013, 26, 173-82.	0.6	16
408	Chloroethylating and methylating dual function antineoplastic agents display superior cytotoxicity against repair proficient tumor cells. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2013, 23, 1853-1859.	1.0	6
409	Randomized trial of chemoradiotherapy and adjuvant chemotherapy with nimustine (ACNU) versus nimustine plus procarbazine for newly diagnosed anaplastic astrocytoma and glioblastoma (JCOG0305). <i>Cancer Chemotherapy and Pharmacology</i> , 2013, 71, 511-521.	1.1	25
410	Inhibiting the <sc>DNA</sc> damage response as a therapeutic manoeuvre in cancer. <i>British Journal of Pharmacology</i> , 2013, 169, 1745-1765.	2.7	64
411	The expression of O<sup>6</sup>-methylguanineâ€<sc>DNA</sc> methyltransferase in human oral keratinocytes stimulated with arecoline. <i>Journal of Oral Pathology and Medicine</i> , 2013, 42, 600-605.	1.4	12
412	Hypoxia-Selective <i>O</i><sup>6</sup>-Alkylguanine-DNA Alkyltransferase Inhibitors: Design, Synthesis, and Evaluation of 6-(Benzyloxy)-2-(aryldiazenyl)-9<i>H</i>-purines as Prodrugs of <i>O</i><sup>6</sup>-Benzylguanine. <i>Journal of Medicinal Chemistry</i> , 2013, 56, 1355-1359.	2.9	23
413	A Newly Uncovered Group of Distantly Related Lysine Methyltransferases Preferentially Interact with Molecular Chaperones to Regulate Their Activity. <i>PLoS Genetics</i> , 2013, 9, e1003210.	1.5	138
414	Correlation of MLH1 and MGMT methylation levels between peripheral blood leukocytes and colorectal tissue DNA samples in colorectal cancer patients. <i>Oncology Letters</i> , 2013, 6, 1370-1376.	0.8	11
415	Recent Advances in Glioblastoma Treatment. <i>Journal of the Nihon University Medical Association</i> , 2013, 72, 43-51.	0.0	0
416	Maotai Ameliorates Diethylnitrosamine-Initiated Hepatocellular Carcinoma Formation in Mice. <i>PLoS ONE</i> , 2014, 9, e93599.	1.1	21
417	Prognostic and Predictive Roles of MGMT Protein Expression and Promoter Methylation in Sporadic Pancreatic Neuroendocrine Neoplasms. <i>Neuroendocrinology</i> , 2014, 100, 35-44.	1.2	76
418	Quantification of DNA interstrand crosslinks induced by ACNU in NIH/3T3 and L1210 cells using high-performance liquid chromatography/electrospray ionization tandem mass spectrometry. <i>Rapid Communications in Mass Spectrometry</i> , 2014, 28, 439-447.	0.7	11
419	The Role of Gene Body Cytosine Modifications in <i>MGMT</i> Expression and Sensitivity to Temozolomide. <i>Molecular Cancer Therapeutics</i> , 2014, 13, 1334-1344.	1.9	40



#	ARTICLE	IF	CITATIONS
420	Phosphatidylinositol 3-kinases inhibitor LY294002 potentiates the cytotoxic effects of doxorubicin, vincristine, and etoposide in a panel of cancer cell lines. <i>Fundamental and Clinical Pharmacology</i> , 2014, 28, 414-422.	1.0	20
421	DNA Methylation as a Biomarker in Nasopharyngeal Carcinoma. , 2014, , 1-18.		0
422	The molecular significance of methylated BRCA1 promoter in white blood cells of cancer-free females. <i>BMC Cancer</i> , 2014, 14, 830.	1.1	38
423	Predictive biomarkers for cancer therapy with PARP inhibitors. <i>Oncogene</i> , 2014, 33, 3894-3907.	2.6	89
424	Insight into the cooperative DNA binding of the O6-alkylguanine DNA alkyltransferase. <i>DNA Repair</i> , 2014, 20, 14-22.	1.3	8
425	Immunohistochemical analysis of O6-methylguanine-DNA methyltransferase in human melanoma in comparison with skin squamous cell carcinoma. <i>Medical Molecular Morphology</i> , 2014, 47, 8-13.	0.4	2
426	Influence of promoter/enhancer region haplotypes on MGMT transcriptional regulation: a potential biomarker for human sensitivity to alkylating agents. <i>Carcinogenesis</i> , 2014, 35, 564-571.	1.3	16
427	Inhibition of DNA Repair as a Therapeutic Target. , 2014, , 193-237.		0
428	Nanotherapeutic approaches for brain cancer management. <i>Nanomedicine: Nanotechnology, Biology, and Medicine</i> , 2014, 10, e905-e919.	1.7	87
429	MGMT gene silencing by promoter hypermethylation in gastric cancer in a high incidence area. <i>Cellular Oncology (Dordrecht)</i> , 2014, 37, 245-252.	2.1	27
430	Redox-Responsive Magnetic Nanoparticle for Targeted Convection-Enhanced Delivery of <i>O<sup>6</sup>-Benzylguanine</i> to Brain Tumors. <i>ACS Nano</i> , 2014, 8, 10383-10395.	7.3	157
431	Combination Treatment with Theranostic Nanoparticles for Glioblastoma Sensitization to TMZ. <i>Molecular Imaging and Biology</i> , 2014, 16, 680-689.	1.3	37
432	Response of primary glioblastoma cells to therapy is patient specific and independent of cancer stem cell phenotype. <i>Neuro-Oncology</i> , 2014, 16, 361-371.	0.6	42
433	Delineating an epigenetic continuum in head and neck cancer. <i>Cancer Letters</i> , 2014, 342, 178-184.	3.2	37
434	Higher LRRFIP1 expression in glioblastoma multiforme is associated with better response to teniposide, a type II topoisomerase inhibitor. <i>Biochemical and Biophysical Research Communications</i> , 2014, 446, 1261-1267.	1.0	11
435	Antitumorigenic effect of interferon- $\gamma$ by inhibition of undifferentiated glioblastoma cells. <i>International Journal of Oncology</i> , 2015, 47, 1647-1654.	1.4	8
436	Frequency of <i>O<sup>6</sup>-methylguanine-DNA</i> methyltransferase promoter methylation in cytological samples from small cell lung cancer. <i>Diagnostic Cytopathology</i> , 2015, 43, 947-952.	0.5	13
437	Somatic mutations in glioblastoma are associated with methylguanine-DNA methyltransferase methylation. <i>Oncology Letters</i> , 2015, 9, 2063-2067.	0.8	16

#	ARTICLE	IF	CITATIONS
438	Direct Reversal Repair in Mammalian Cells. , 0, , .		3
439	Prediction of Cancer Drug Resistance and Implications for Personalized Medicine. <i>Frontiers in Oncology</i> , 2015, 5, 282.	1.3	77
440	Influence of the Expression Level of O6-Alkylguanine-DNA Alkyltransferase on the Formation of DNA Interstrand Crosslinks Induced by Chloroethylnitrosoureas in Cells: A Quantitation Using High-Performance Liquid Chromatography-Mass Spectrometry. <i>PLoS ONE</i> , 2015, 10, e0121225.	1.1	6
441	Atomic Insight into the Altered O6-Methylguanine-DNA Methyltransferase Protein Architecture in Gastric Cancer. <i>PLoS ONE</i> , 2015, 10, e0127741.	1.1	9
442	Expression and promoter methylation status of <i>hMLH1</i> , <i>MGMT</i> , <i>APC</i> , and <i>CDH1</i> genes in patients with colon adenocarcinoma. <i>Experimental Biology and Medicine</i> , 2015, 240, 1599-1605.	1.1	42
443	Regulation of expression of O6-methylguanine-DNA methyltransferase and the treatment of glioblastoma (Review). <i>International Journal of Oncology</i> , 2015, 47, 417-428.	1.4	103
444	The impact of base excision DNA repair in age-related neurodegenerative diseases. <i>Mutation Research - Fundamental and Molecular Mechanisms of Mutagenesis</i> , 2015, 776, 31-39.	0.4	59
445	Prognostic value of MGMT methylation in colorectal cancer: a meta-analysis and literature review. <i>Tumor Biology</i> , 2015, 36, 1595-1601.	0.8	21
446	Clinicopathological significance and potential drug target of O6-methylguanine-DNA methyltransferase in colorectal cancer: a meta-analysis. <i>Tumor Biology</i> , 2015, 36, 5839-5848.	0.8	8
447	<i>O<sup>6</sup></i> -methylguanine DNA methyltransferase repairs platinum-DNA adducts following cisplatin treatment and predicts prognoses of nasopharyngeal carcinoma. <i>International Journal of Cancer</i> , 2015, 137, 1291-1305.	2.3	30
448	Protein expression and methylation of MGMT, a DNA repair gene and their correlation with clinicopathological parameters in invasive ductal carcinoma of the breast. <i>Tumor Biology</i> , 2015, 36, 6485-6496.	0.8	20
449	Chemotherapeutic effect of tamoxifen on temozolomide-resistant gliomas. <i>Anti-Cancer Drugs</i> , 2015, 26, 293-300.	0.7	32
450	Synthesis of oligonucleotides carrying fluorescently labelled O6-alkylguanine for measuring hAGT activity. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2015, 25, 5208-5211.	1.0	5
451	Evaluation of extracellular matrix protein CCN1 as a prognostic factor for glioblastoma. <i>Brain Tumor Pathology</i> , 2015, 32, 245-252.	1.1	15
452	Aberrant Methylation of MGMT Promoter in HNSCC: A Meta-Analysis. <i>PLoS ONE</i> , 2016, 11, e0163534.	1.1	12
453	Cellular response to alkylating agent <i>MNNG</i> is impaired in <i>STAT1</i> deficient cells. <i>Journal of Cellular and Molecular Medicine</i> , 2016, 20, 1956-1965.	1.6	7
454	Can the response to a platinum-based therapy be predicted by the DNA repair status in non-small cell lung cancer?. <i>Cancer Treatment Reviews</i> , 2016, 48, 8-19.	3.4	26
455	DNA-repair defects in pancreatic neuroendocrine tumors and potential clinical applications. <i>Cancer Treatment Reviews</i> , 2016, 44, 1-9.	3.4	14

#	ARTICLE	IF	CITATIONS
456	Synthesis and antitumor activity evaluation of a novel combi-nitrosourea prodrug: Designed to release a DNA cross-linking agent and an inhibitor of O6-alkylguanine-DNA alkyltransferase. <i>Bioorganic and Medicinal Chemistry</i> , 2016, 24, 2097-2107.	1.4	20
457	Measurement of O <sup>6</sup> -alkylguanine-DNA alkyltransferase activity in tumour cells using stable isotope dilution HPLC-ESI-MS/MS. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2016, 1033-1034, 138-146.	1.2	7
458	Phase 1 trial of vocimagene amiretrorepvec and 5-fluorocytosine for recurrent high-grade glioma. <i>Science Translational Medicine</i> , 2016, 8, 341ra75.	5.8	158
459	MGMT DNA repair gene promoter/enhancer haplotypes alter transcription factor binding and gene expression. <i>Cellular Oncology (Dordrecht)</i> , 2016, 39, 435-447.	2.1	7
460	In-Geno Quantification of O <sup>6</sup> -Methylguanine with Elongated Nucleoside Analogues on Gold Nanoprobes. <i>Journal of the American Chemical Society</i> , 2016, 138, 8497-8504.	6.6	16
461	BRCA1 promoter methylation in peripheral blood cells and predisposition to breast cancer. <i>Journal of Taibah University Medical Sciences</i> , 2017, 12, 189-193.	0.5	2
462	A phase 2 study of temozolomide in pretreated metastatic colorectal cancer with MGMT promoter methylation. <i>British Journal of Cancer</i> , 2017, 116, 1279-1286.	2.9	37
463	Mapping clinicopathological entities within colorectal mucinous adenocarcinomas: a hierarchical clustering approach. <i>Modern Pathology</i> , 2017, 30, 1177-1189.	2.9	19
464	Association of O <sup>6</sup> -Methylguanine-DNA Methyltransferase Protein Expression With Postoperative Prognosis and Adjuvant Chemotherapeutic Benefits Among Patients With Stage II or III Gastric Cancer. <i>JAMA Surgery</i> , 2017, 152, e173120.	2.2	22
465	The proline rich domain of p53 is dispensable for MGMT-dependent DNA repair and cell survival following alkylation damage. <i>Cell Death and Differentiation</i> , 2017, 24, 1925-1936.	5.0	10
466	O <sup>6</sup> -Methylguanine-DNA methyltransferase (MGMT): A drugable target in lung cancer?. <i>Lung Cancer</i> , 2017, 107, 91-99.	0.9	19
468	Efficacy of ribavirin against malignant glioma cell lines: Follow-up study. <i>Oncology Reports</i> , 2018, 39, 537-544.	1.2	9
469	MicroRNA Regulation of Glycolytic Metabolism in Glioblastoma. <i>BioMed Research International</i> , 2017, 2017, 1-13.	0.9	24
470	Clinical importance of DNA repair in sporadic colorectal cancer. <i>Critical Reviews in Oncology/Hematology</i> , 2018, 126, 168-185.	2.0	11
471	MGMT pyrosequencing-based cut-off methylation level and clinical outcome in patients with glioblastoma multiforme. <i>Future Oncology</i> , 2018, 14, 699-707.	1.1	29
472	Tissue is the Issue: Biomarkers of Prognosis and Classification in Adult Gliomas. <i>Seminars in Oncology Nursing</i> , 2018, 34, 430-442.	0.7	5
473	Genetic testing for high-grade osteosarcoma: a guide for future tailored treatments?. <i>Expert Review of Molecular Diagnostics</i> , 2018, 18, 947-961.	1.5	12
474	Carcinogenic Alkylating Agents. , 2018, , 68-86.		1

#	ARTICLE	IF	CITATIONS
475	Methyltransferases. , 2018, , 497-516.		0
476	Defining a prognostic score based on O6-methylguanine-DNA methyltransferase cut-off methylation level determined by pyrosequencing in patients with glioblastoma multiforme. Journal of Neuro-Oncology, 2018, 140, 559-568.	1.4	9
477	A systematic review and quantitative assessment of methylation biomarkers in fecal DNA and colorectal cancer and its precursor, colorectal adenoma. Mutation Research - Reviews in Mutation Research, 2019, 779, 45-57.	2.4	31
478	Hypoxia-targeted drug delivery. Chemical Society Reviews, 2019, 48, 771-813.	18.7	350
479	Repair and translesion synthesis of O6-alkylguanine DNA lesions in human cells. Journal of Biological Chemistry, 2019, 294, 11144-11153.	1.6	21
480	DNA repair in personalized brain cancer therapy with temozolomide and nitrosoureas. DNA Repair, 2019, 78, 128-141.	1.3	89
481	Reductive Activity and Mechanism of Hypoxia- Targeted AGT Inhibitors: An Experimental and Theoretical Investigation. International Journal of Molecular Sciences, 2019, 20, 6308.	1.8	5
482	Refining the selection of patients with metastatic colorectal cancer for treatment with temozolomide using proteomic analysis of O6-methylguanine-DNA-methyltransferase. European Journal of Cancer, 2019, 107, 164-174.	1.3	9
483	Study of aldehyde oxidase by micellar electrokinetic chromatography separation of O <sup>6</sup> -methylguanine and O <sup>6</sup> -methylguanine. Electrophoresis, 2019, 40, 330-335.	1.3	4
484	Downregulation of MGMT promotes proliferation of intrahepatic cholangiocarcinoma by regulating p21. Clinical and Translational Oncology, 2020, 22, 392-400.	1.2	13
485	DNA Damage Response and Immune Defense. International Journal of Molecular Sciences, 2020, 21, 7504.	1.8	66
486	Hybrid lipid self-assembling nanoparticles for brain delivery of microRNA. International Journal of Pharmaceutics, 2020, 588, 119693.	2.6	19
487	Radioresistance in Glioblastoma and the Development of Radiosensitizers. Cancers, 2020, 12, 2511.	1.7	77
488	Genomics and Therapeutic Vulnerabilities of Primary Bone Tumors. Cells, 2020, 9, 968.	1.8	19
489	Molecular and Clinicopathological Characterization of a Prognostic Immune Gene Signature Associated With MGMT Methylation in Glioblastoma. Frontiers in Cell and Developmental Biology, 2021, 9, 600506.	1.8	5
490	Clinical and epigenetic features of colorectal cancer patients with somatic POLE proofreading mutations. Clinical Epigenetics, 2021, 13, 117.	1.8	8
491	Role of Hydrazine-Related Chemicals in Cancer and Neurodegenerative Disease. Chemical Research in Toxicology, 2021, 34, 1953-1969.	1.7	18
493	Cis-Acting Factors Causing Secondary Epimutations: Impact on the Risk for Cancer and Other Diseases. Cancers, 2021, 13, 4807.	1.7	8

#	ARTICLE	IF	CITATIONS
494	Mechanisms of Resistance to Alkylating Agents. <i>Cancer Treatment and Research</i> , 1996, 87, 65-81.	0.2	9
495	Role of DNA Repair in Resistance to Drugs that Alkylate O6 of Guanine. <i>Cancer Treatment and Research</i> , 1996, 87, 123-146.	0.2	13
496	Treatment of Brain Tumors. <i>Advances in Delivery Science and Technology</i> , 2014, , 169-194.	0.4	1
497	Genetics of drug resistance. <i>Cancer Treatment and Research</i> , 1994, 73, 1-16.	0.2	3
498	Mechanisms of resistance to alkylating agents. <i>Cancer Treatment and Research</i> , 1994, 73, 249-262.	0.2	9
499	DNA Repair Pathways and Cancer Prevention. <i>Advances in Experimental Medicine and Biology</i> , 1999, 472, 253-267.	0.8	6
500	Epidemiology of Primary Brain Tumors. , 2001, , 47-71.		1
501	Cellular Responses to Methylation Damage. , 1998, , 33-49.		3
502	Development of the Nitrosoureas. , 1997, , 81-92.		3
503	Relevance of DNA Repair to Carcinogenesis and Cancer Therapy. <i>Recent Results in Cancer Research</i> , 1998, 154, 127-146.	1.8	21
504	DNA Mismatch Repair. <i>Nucleic Acids and Molecular Biology</i> , 1998, , 173-197.	0.2	4
505	Is there a future for the small molecule in developmental cancer chemotherapy?. <i>Cancer Biology and Medicine</i> , 1992, , 1-17.	0.1	1
506	Changes in alkylation damage removal during in vitro neuronal differentiation. <i>Acta Biologica Hungarica</i> , 1997, 48, 113-120.	0.7	1
507	Methyltransferases. , 2010, , 435-457.		8
508	Artificial control of nuclear translocation of DNA repair methyltransferase.. <i>Journal of Biological Chemistry</i> , 1994, 269, 7645-7650.	1.6	22
509	Repair of O6-methylguanine and O4-methylthymine by the human and rat O6-methylguanine-DNA methyltransferases.. <i>Journal of Biological Chemistry</i> , 1994, 269, 730-733.	1.6	56
510	O6-methylguanine residues elicit DNA repair synthesis by human cell extracts. <i>Journal of Biological Chemistry</i> , 1993, 268, 15878-15886.	1.6	58
511	The role of the carboxyl-terminal tail in human O6-methylguanine DNA methyltransferase substrate specificity and temperature sensitivity.. <i>Journal of Biological Chemistry</i> , 1993, 268, 19802-19809.	1.6	14

#	ARTICLE	IF	CITATIONS
512	Molecular and cellular characterization of Mex-/methylation-resistant phenotype. Gene and cDNA cloning, serum dependence, and tumor suppression of transfectant strains.. Journal of Biological Chemistry, 1993, 268, 21102-21112.	1.6	8
513	Human cytidine deaminase as an ex vivo drug selectable marker in gene-modified primary bone marrow stromal cells. , 0, .		1
514	Real-Time Methylation-Specific Polymerase Chain Reaction for MGMT Promoter Methylation Clinical Testing in Glioblastoma. American Journal of Clinical Pathology, 2017, 148, 296-307.	0.4	5
516	Inducibility of the DNA Repair Gene Encoding <i>O<sup>6</sup>-Methylguanine- DNA Methyltransferase</i> in Mammalian Cells by DNA-Damaging Treatments. Molecular and Cellular Biology, 1991, 11, 4660-4668.	1.1	53
517	Glutathione, cell proliferation, and 1,3-bis-(2-chloroethyl)-1-nitrosourea in K562 leukemia.. Journal of Clinical Investigation, 1993, 92, 2761-2767.	3.9	24
518	Hypermethylation of the Putative Tumor-suppressor Genes DCC, p51/63 and O6-methylguanine-DNA Methyltransferase (MGMT) and Loss of Their Expressions in Cell Lines of Hematological Malignancies. Journal of Nippon Medical School, 2005, 72, 270-277.	0.3	2
519	Role of MGMT as biomarker in colorectal cancer. World Journal of Clinical Cases, 2014, 2, 835.	0.3	27
520	Altered Expression of MGMT in High-Grade Gliomas Results from the Combined Effect of Epigenetic and Genetic Aberrations. PLoS ONE, 2013, 8, e58206.	1.1	28
521	Early Chk1 Phosphorylation Is Driven by Temozolomide-Induced, DNA Double Strand Break- and Mismatch Repair-Independent DNA Damage. PLoS ONE, 2013, 8, e62351.	1.1	26
522	Genetic and Epigenetic Alterations in Primary Progressive Paired Oligodendroglial Tumors. PLoS ONE, 2013, 8, e67139.	1.1	6
523	Immunohistochemical Assessment of <i>O<sup>6</sup>-Methylguanine-DNA Methyltransferase (MGMT)</i> and Its Relationship with p53 Expression in Endometrial Cancers. Journal of Cancer Prevention, 2013, 18, 351-354.	0.8	10
524	Reduction of MLH1 and PMS2 confers temozolomide resistance and is associated with recurrence of glioblastoma. Oncotarget, 2013, 4, 2261-2270.	0.8	67
525	A genome-wide miRNA screen revealed miR-603 as a MGMT-regulating miRNA in glioblastomas. Oncotarget, 2014, 5, 4026-4039.	0.8	62
526	IDH mutation and MGMT promoter methylation in glioblastoma: results of a prospective registry. Oncotarget, 2015, 6, 40896-40906.	0.8	116
527	Reappraisal of the use of procarbazine in the treatment of lymphomas and brain tumors. Therapeutics and Clinical Risk Management, 2007, 3, 213-224.	0.9	29
528	Molecular characterization of head and neck cancer: how close to personalized targeted therapy?. Molecular Diagnosis and Therapy, 2012, 16, 209-22.	1.6	14
529	Dietary phytate lowers - mutational frequency, decreases DNA-adduct and hydroxyl radical formation in azoxymethane-induced colon cancer. Iranian Journal of Basic Medical Sciences, 2020, 23, 20-29.	1.0	5
530	Methylation Status of the <i>O6-Methylguanine- Deoxyribonucleic Acid Methyltransferase Gene Promoter</i> in World Health Organization Grade III Gliomas. Journal of Korean Neurosurgical Society, 2009, 46, 385.	0.5	6

#	ARTICLE	IF	CITATIONS
531	Comethylation of p16 and MGMT genes in colorectal carcinoma: Correlation with clinicopathological features and prognostic value. <i>World Journal of Gastroenterology</i> , 2007, 13, 1187.	1.4	40
532	Role of Loss of O <sup>6</sup> -Methylguanine DNA Methyltransferase (MGMT) Expression in Non-Small Cell Lung Carcinomas (NSCLCs): with Reference to the Relationship with p53 Overexpression. <i>Cancer Research and Treatment</i> , 2010, 42, 95.	1.3	6
533	Role of O <sup>6</sup> -alkylguanine-DNA alkyltransferase in repairing lesions, induced by alkylating compounds. <i>Biopolymers and Cell</i> , 2001, 17, 265-277.	0.1	2
534	Unboxing the molecular modalities of mutagens in cancer. <i>Environmental Science and Pollution Research</i> , 2022, 29, 62111-62159.	2.7	19
535	DNA Repair. , 2000, , 128-153.		0
536	DNA Repair in Resistance to Bifunctional Alkylating and Platinating Agents. <i>Cancer Treatment and Research</i> , 2002, 112, 129-160.	0.2	1
539	New Therapeutic Approaches to Myeloma. , 2004, , 319-353.		0
540	Chemotherapy for Malignant Gliomas : Randomized Controlled Study and Taylor-made Therapy. <i>Japanese Journal of Neurosurgery</i> , 2006, 15, 3-9.	0.0	0
541	Molecular Genetics of Lung and Pleural Neoplasms. , 2008, , 47-157.		2
542	Role of DNA Methylation in Cancer Progression. , 2008, , 79-93.		0
544	Diffuse Astrocytomas: Immunohistochemistry of MGMT Expression. , 2012, , 89-94.		0
546	Reversal of Alkylation Damage in DNA. , 0, , 139-168.		0
547	The Role of O <sup>6</sup> -Alkylguanine-DNA Alkyltransferase in Glioma in Resistance to Chloroethylnitrosoureas. , 1991, , 260-265.		0
548	CARCINOGENESIS AND DNA REPAIR IN TRANSGENIC MICE. , 1992, , 280-286.		0
549	Genetic Alterations and Gene Expression in Human Malignant Glioma. , 1994, , 143-168.		0
550	Protection of Hematopoietic Progenitor Cells from Chemotherapy Toxicity by Transfer of Drug Resistance Genes. , 1998, , 153-181.		0
551	Nucleotide excision repair and anti-cancer chemotherapy. , 1998, , 187-201.		1
552	Drug resistance and DNA repair in leukaemia. , 1998, , 175-185.		0

#	ARTICLE	IF	CITATIONS
553	Drug Resistance in Breast Cancer. , 1999, , 481-517.		5
554	Transfer of Drug Resistance Genes into Bone Marrow Stem and Progenitor Cells: Implications for Cancer Chemotherapy. Blood Cell Biochemistry, 1999, , 293-312.	0.3	0
555	Primary and Metastatic Brain Tumors. , 1999, , 889-922.		0
556	DNA Methylation as a Biomarker in Nasopharyngeal Carcinoma. Biomarkers in Disease, 2015, , 827-847.	0.0	0
557	Oxidative Damage of Genome DNA: Repair Mechanisms. , 2008, , 49-62.		0
558	The nuclear targeting and nuclear retention properties of a human DNA repair protein O6-methylguanine-DNA methyltransferase are both required for its nuclear localization: the possible implications. EMBO Journal, 1996, 15, 4050-60.	3.5	8
559	Deletion mapping of gliomas suggest the presence of two small regions for candidate tumor-suppressor genes in a 17-cM interval on chromosome 10q. American Journal of Human Genetics, 1996, 58, 1260-7.	2.6	55
560	Histone/protein deacetylase SIRT1 is an anticancer therapeutic target. American Journal of Cancer Research, 2014, 4, 211-21.	1.4	14
561	Spectrum of DNA mismatch repair failures viewed through the lens of cancer genomics and implications for therapy. Clinical Science, 2022, 136, 383-404.	1.8	8
562	Interactions between HIV protease inhibitor ritonavir and human DNA repair enzyme ALKBH2: a molecular dynamics simulation study. Molecular Diversity, 2022, , 1.	2.1	0
563	<i>O</i> <sup>6</sup> -Methylguanine-DNA Methyltransferase Gene: Epigenetic Silencing and Prognostic Value in Head and Neck Squamous Cell Carcinoma. Cancer Epidemiology Biomarkers and Prevention, 2004, 13, 967-975.	1.1	58